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This invention relates to methods for increasing lipid accu 
mulation and lipid production in cells . Methods of produc 
ing biofuel from cells and preparing nutraceuticals compris ing lipids produced according to a method provided herein 
are also provided . 
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COMPOUNDS FOR INCREASING LIPID 
SYNTHESIS AND STORAGE 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
[ 0001 ] This application is a continuation of U.S. patent 
application Ser . No. 15 / 138,066 filed Apr. 25 , 2016 , which 
claims the benefit of U.S. Provisional Application Ser . No. 
62 / 152,717 , filed Apr. 24 , 2015 , the disclosure of which is 
incorporated herein by reference in its entirety . 
[ 0011 ] Rºy is selected from the group consisting of halo , C - 4 alkyl , C -4 alkoxy , phenyl , - ( C -4 alkylene ) - ( phenyl ) , 
Cz.10 cycloalkyl , and ( C - 4 alkylene ) - ( Cz.10 cyloalkyl ) , 
wherein each phenyl and the phenyl group of — ( C1-4 
alkylene ) - ( phenyl ) is optionally substituted by 1 or 2 sub 
stituents independently selected from the group consisting of 
OH , halo , C1-4 alkyl , and C1-4 alkoxy ; 
[ 0012 ] n is 0 or 1 ; and 
[ 0013 ] p is 0 , 1 , 2 , 3 , 4 , or 5 ; or 
[ 0014 ] a compound of Formula Ib : 
FEDERALLY SPONSORED RESEARCH OR 
DEVELOPMENT 
Ib 
RCy NO2 [ 0002 ] This invention was made with Government support 
under Grant Nos . EPS - 1004094 and 1264409 , awarded by 
the National Science Foundation . The Government has 
certain rights in the invention . R4 
TECHNICAL FIELD 
[ 0003 ] This invention relates to methods for increasing 
lipid accumulation and lipid production in cells . 
BACKGROUND 
[ 0004 ] Algae are a diverse group of microorganisms that 
include species that inhabit marine , freshwater and terres 
trial niches . It is estimated that 30-50 % of the net photo 
synthetic productivity on plant earth is contributed by phy 
toplankton including algae . Algae may also be employed for 
the production of biofuels , and can be grown in poor quality 
water and under a large variety of environmental conditions ( see , e.g. , Singh et al . , Bioresource Technology , 2011 , 102 , 
26-34 and Hu et al . , The Plant Journal , 2008 , 54 , 621-639 ) . Additionally , during photosynthesis algae fix Co , into bio 
mass thus addressing concerns about the generation of 
carbon emissions . 
or a pharmaceutically acceptable salt thereof , wherein : 
[ 0015 ] L is selected from the group consisting of a bond , C - 4 alkylene , C - 4 hydroxyalkylene , and C ( = O ) ; 
[ 0016 ] R4 is selected from the group consisting of H and piperidinyl , and 
[ 0017 ] RMis selected from the group consisting of C1-4 
alkyl , phenyl , – ( C1-4 alkylene ) - ( phenyl ) , C3-10 cycloalkyl , 
and ( C - 4 alkylene ) - ( C3-10 cyloalkyl ) , wherein each phe 
nyl and the phenyl group of C - 4 alkylene ) - ( phenyl ) is 
optionally substituted by 1 or 2 substituents independently 
selected from the group consisting of OH , halo , C -4 alkyl , 
and C - 4 alkoxy ; or 
[ 0018 ] a compound of Formula Ic : 
Ic 
SUMMARY 13 NO2 R3a [ 0005 ] The present application provides , inter alia , a 
method of increasing lipid accumulation in a cell , compris ing contacting the cell with an effective amount of a com 
pound of Formula Ia : 
Za -Rta 
Ia 
R3 NO2 ( RCY ) 
R4 
or a pharmaceutically acceptable salt thereof , wherein : 
[ 0006 ] L is selected from the group consisting of a bond , 
C - 4 alkylene , C1-4 hydroxyalkylene , C - 4 alkyleneoxy , ( C1-4 alkylene ) -NR ( C1-4 alkylene ) n , CEO ) , and 
C ( 0 ) NH ; 
[ 0007 ] RP is selected from the group consisting of H and 
methyl ; 
[ 0008 ] R3 is H or C1-4 alkoxy ; [ 0009 ] R4 is selected from the group consisting of H and piperidinyl ; 
[ 0010 ] Cyl is selected from the group consisting of phe 
nyl , Cz.g cycloalkyl , 4-6 membered heterocycloalkyl , and 
4-10 membered heteroaryl ; 
or a pharmaceutically acceptable salt thereof , wherein : 
[ 0019 ) L ' is selected from the group consisting of a bond 
and C ( O ) NH ; 
[ 0020 ] R3a is selected from the group consisting of H , C1-4 
alkyl , C1-4 alkoxy , -phenyl- ( C1-4 alkylene ) -R ” , - ( phenyl ) 
SO , R " , and 5-6 membered heteroaryl , wherein the 5-6 
membered heteroaryl is optionally substituted with a C1-4 
alkyl group : 
[ 0021 ] Rois selected from the group consisting of 5-6 
membered heteroaryl and 5-6 membered heterocycloalkyl , 
wherein the 5-6 membered heterocycloalkyl is optionally 
substituted by a C2-4 alkyl group ; 
[ 0022 ] L * is selected from the group consisting of a bond , S , CEO ) NH , C1-6 alkyleneoxy , and SO2 - Cy2 - Cys ; 
[ 0023 ] Cy and Cy are each an independently selected 5-6 
membered heterocycloalkyl group ; and 
[ 0024 ] R4a is selected from the group consisting of H , C1-4 
alkyl , ( C - 4 alkylene ) - ( C3-6 cycloalkyl ) , 5-6 membered 
heterocyloalkyl , and ( C1-4 alkylene ) - ( phenyl ) ; or 
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[ 0025 ] a compound of Formula IIa : 
Ila 
R3 
R2 
R5 
R4 
N 
" R la 
or a pharmaceutically acceptable salt thereof , wherein : [ 0026 ] L ' is selected from the group consisting of a bond , C - 4 alkylene , C2-4 alkenylene , C - 4 hydroxyalkylene , C - 4 
alkyleneoxy , 4-6 membered heterocycloalkylene , and 
CO ), wherein the C -4 alkyleneoxy is further optionally 
substituted by one OH group ; [ 0027 ] Rla is selected from the group consisting of OH , 
C - 4 alkyl , C5-10 cycloalkyl , 8-10 membered heteroaryl , 
phenyl , ( C1-4 alkylene ) - ( phenyl ) , and 10-13 membered 
heteroaryl , wherein the C5-10 cycloalkyl , phenyl , and the 
phenyl group of the ( C1.4 alkylene ) - ( phenyl ) are each 
optionally substituted by 1 , 2 , or 3 substituents indepen 
dently selected from the group consisting of halo , OH , NO2 , 
C1-4 alkyl , and C1-4 alkoxy , and wherein the 10-13 mem bered heteroaryl is optionally substituted by one halo group ; 
[ 0028 ] R² is selected from the group consisting of H , halo , 
OH , NO2 , C1-4 alkyl , C - 4 alkoxy , and— ( C - 4 alkylene ) - ( 8 
10 membered heteroaryl ) ; [ 0029 ] R² is selected from the group consisting of H , halo , 
C1-4 alkoxy , and phenoxy ; or alternatively , R2 and R3 come 
together , in combination with the carbon atoms to which 
they are attached , to form a 5-6 membered heterocycloalkyl 
or a C6-10 aryl ; [ 0030 ] R4 is selected from the group consisting of H , OH , 
and C1-4 alkoxy ; [ 0031 ] R?is selected from the group consisting of H , halo , 
C1-4 alkoxy , and phenoxy ; and 
[ 0032 ] Róis selected from the group consisting of H and 
oxo ; or 
[ 0033 ] a compound of Formula IIIa : 
alkylene ) - , wherein the C1-6 alkyleneoxy is further option 
ally substituted by one OH group ; [ 0035 ] Rla is selected from the group consisting of H , C1-4 
alkyl , C2-4 alkenyl , C - 4 cyanoalkylene , 5-6 membered het 
erocycloalkyl , 5-6 membered heteroaryl , NH ( C1-4 alkyl ) , 
and NH ( C2-4 alkenyl ) , wherein the C1-4 alkyl and C2-4 
alkenyl are each optionally substituted by one substituent 
selected from the group consisting of phenyl and hydroxy 
phenyl , and wherein the 5-6 membered heterocycloalkyl and 
5-6 membered heteroaryl are each optionally substituted by 
1 or 2 substituents independently selected from the group 
consisting of C1-4 alkyl , NH , and di - halo substituted phenyl ; [ 0036 ] L ’ is selected from the group consisting of a bond 
and 5-6 membered heterocycloalkyl ; and 
[ 0037 ] R24 is selected from the group consisting of H , C1-4 
hydroxyalkyl , -SO ( C - 4 alkyl ) . 
[ 0038 ] In some embodiments , the compound is a com 
pound of Formula Ia . In some embodiments , the compound is a compound of Formula II . In some embodiments , the 
compound is a compound of Formula IIIa . 
[ 0039 ] In some embodiments , the cell is a eukaryotic cell 
or a cyanobacteria . In some embodiments , the cell is 
selected from the group consisting of an algal cell , a 
drosophila cell , a yeast cell , or a fungus cell . In some 
embodiments , the cell is an algal cell . In some embodiments , 
the cell is selected from the group consisting of : 
[ 0040 ] Chlamydomonas reinhardtii ; 
[ 0041 ] Chlorella sorokiniana ; 
[ 0042 ] Tetrachlorella alterans ; [ 0043 ] C. protothecoides ; 
[ 0044 ] C. vulgaris , and 
[ 0045 ] Nannochloropsis sp . 
[ 0046 ] In some embodiments , the increasing lipid accu 
mulation comprises increasing fatty acid accumulation . In 
some embodiments , the increasing lipid accumulation com 
prises increasing polyunsaturated fatty acid accumulation . In 
some embodiments , the increasing lipid accumulation com prises increasing triacylglycerol accumulation . In some 
embodiments , the increasing lipid accumulation comprises 
increasing fatty acid accumulation and increasing triacyl 
glycerol accumulation . In some embodiments , the increas ing lipid accumulation comprises increasing polyunsatu 
rated fatty acid accumulation and increasing triacylglycerol 
accumulation . 
[ 0047 ] In some embodiments , the method further com 
prises increasing carbohydrate accumulation in the cell . In 
some embodiments , the method further comprises increas ing carbohydrate production in the cell . 
[ 0048 ] In some embodiments , the lipid accumulation is increased by greater than about 1.5 - fold as compared to a 
cell that has not been contacted by the compound . In some 
embodiments , the lipid accumulation is increased by greater 
than about 2 - fold as compared to a cell that has not been 
contacted by the compound . In some embodiments , the lipid 
accumulation is increased by greater than about 2.5 - fold as 
compared to a cell that has not been contacted by the 
compound . 
[ 0049 ] In some embodiments , the contacting the cell with 
the compound does not reduce the rate of cellular growth 
compared to a cell that has not been contacted by the 
compound . In some embodiments , contacting the cell with 
the compound does not reduce the rate of photosynthesis of 
the cell compared to a cell that has not been contacted by the 
IIIa 
a ( 2 - ne R 
or a pharmaceutically acceptable salt thereof , wherein : 
[ 0034 ] L ' is selected from the group consisting of a bond , 
NH , N ( C1-4 alkyl ) , C2-4 alkynyl , NHC ( O ) ( C1-4 thioalkyl ) , 
C - 6 alkyleneoxy , 5-6 membered heterocycloalkyl , NHC 
( 0 ) C -4 alkylene , and ( C1-4 alkylene ) -NHC ( O ) - ( C1-4 
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optionally substituted by 1 or 2 substituents independently 
selected from the group consisting of OH , halo , C -4 alkyl , 
and C1-4 alkoxy ; or [ 0064 ] a compound of Formula Ic : 
Ic 
compound . In some embodiments , the contacting does not 
adversely affect the viability of the cell . 
[ 0050 ] In some embodiments , the lipid accumulation is 
increased without exposing the cell to environmental stress . 
In some embodiments , the environmental stress comprises 
nutrient deprivation . In some embodiments , the environ 
mental stress comprises depriving the cell of nitrogen , 
depriving the cell of sulfur , depriving the cell of metal , or 
any combination thereof . In some embodiments , the envi 
ronmental stress comprises depriving the cell of nitrogen , 
depriving the cell of sulfur , depriving the cell of metal , or 
any combination thereof . [ 0051 ] The present application further provides a method 
of increasing lipid production in a cell , comprising contact 
ing the cell with an effective amount of a compound of 
NO2 
R3a 
• Rta 
la 
R3 ( RCY ) , NO2 
R4 
or a pharmaceutically acceptable salt thereof , wherein : [ 0065 ] L ’ is selected from the group consisting of a bond 
and C ( O ) NH ; [ 0066 ] R3a is selected from the group consisting of H , C1-4 
alkyl , C2-4 alkoxy , -phenyl- ( C - 4 alkylene ) -R " , - ( phenyl ) 
SOR " , and 5-6 membered heteroaryl , wherein the 5-6 
membered heteroaryl is optionally substituted with a C - 4 
alkyl group ; [ 0067 ] RP is selected from the group consisting of 5-6 
membered heteroaryl and 5-6 membered heterocycloalkyl , 
wherein the 5-6 membered heterocycloalkyl is optionally 
substituted by a C2-4 alkyl group ; [ 0068 ] L * is selected from the group consisting of a bond , S , CEO ) NH , C1-6 alkyleneoxy , and SO2 - Cy -- Cy ; [ 0069 ] Cy2 and Cy are each an independently selected 5-6 
membered heterocycloalkyl group ; and [ 0070 ] R44 is selected from the group consisting of H , C - 4 
alkyl , ( C - 4 alkylene ) - ( C3.6 cycloalkyl ) , 5-6 membered 
heterocyloalkyl , and ( C1-4 alkylene ) - ( phenyl ) ; or [ 0071 ] a compound of Formula Ila : 
Ila 
or a pharmaceutically acceptable salt thereof , wherein : 
[ 0052 ] L is selected from the group consisting of a bond , C - 4 alkylene , C1-4 hydroxyalkylene , C - 4 alkyleneoxy , 
-C1-4 alkylene ) -NR - C - 4 alkylene ) , - , CEO ) , and 
C ( O ) NH ; 
[ 0053 ] RP is selected from the group consisting of H and 
methyl ; 
[ 0054 ] Ris H or C -4 alkoxy ; [ 0055 ] R * is selected from the group consisting of H and piperidinyl ; 
[ 0056 ] Cyl is selected from the group consisting of phe 
nyl , C3-8 cycloalkyl , 4-6 membered heterocycloalkyl , and 
4-10 membered heteroaryl ; [ 0057 ] Rºy is selected from the group consisting of halo , 
C1-4 alkyl , C1-4 alkoxy , phenyl , ( C1-4 alkylene ) - ( phenyl ) , 
C3-10 cycloalkyl , and — ( C1-4 alkylene ) - ( C3-10 cyloalkyl ) , 
wherein each phenyl and the phenyl group of ( C1-4 
alkylene ) - ( phenyl ) is optionally substituted by 1 or 2 sub 
stituents independently selected from the group consisting of 
OH , halo , C1-4 alkyl , and C1-4 alkoxy ; 
[ 0058 ] n is 0 or 1 ; and 
[ 0059 ] p is 0 , 1 , 2 , 3 , 4 , or 5 ; or [ 0060 ] a compound of Formula Ib : 
R2 
R6 
R5 
R4 
- 
L ! 
Rla 
Ib 
RG NO2 
N 
R4 
or a pharmaceutically acceptable salt thereof , wherein : 
[ 0061 ] L is selected from the group consisting of a bond , 
C1-4 alkylene , C1-4 hydroxyalkylene , and CEO ) ; 
[ 0062 ] R * is selected from the group consisting of H and piperidinyl ; and 
[ 0063 ] Rºy is selected from the group consisting of C1-4 
alkyl , phenyl , ( C1-4 alkylene ) - ( phenyl ) , C3-10 cycloalkyl , 
and ( C - 4 alkylene ) - ( C3-10 cyloalkyl ) , wherein each phe 
nyl and the phenyl group of ( C1-4 alkylene ) - ( phenyl ) is 
or a pharmaceutically acceptable salt thereof , wherein : [ 0072 ] L'is selected from the group consisting of a bond , 
C - 4 alkylene , C24 alkenylene , C - hydroxyalkylene , C1-4 
alkyleneoxy , 4-6 membered heterocycloalkylene , and 
CEO ) , wherein the C1-4 alkyleneoxy is optionally further 
substituted by one OH group ; 
[ 0073 ] Rla is selected from the group consisting of OH , 
C1-4 alkyl , C5-10 cycloalkyl , 8-10 membered heteroaryl , 
phenyl , ( C - 4 alkylene ) - ( phenyl ) , and 10-13 membered 
heteroaryl , wherein the C5-10 cycloalkyl , phenyl , and the 
phenyl group of the C - 4 alkylene ) - ( phenyl ) are each 
optionally substituted by 1 , 2 , or 3 substituents indepen 
dently selected from the group consisting of halo , OH , NO2 , 
C1-4 alkyl , and C1-4 alkoxy , and wherein the 10-13 mem 
bered heteroaryl is optionally substituted by one halo group ; 
9 
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[ 0074 ] R² is selected from the group consisting of H , halo , 
OH , NO ,, C1-4 alkyl , C -4 alkoxy , and ( C1-4 alkylene ) - ( 8 
10 membered heteroaryl ) ; [ 0075 ] R ’ is selected from the group consisting of H , halo , 
C - 4 alkoxy , and phenoxy ; or [ 0076 ] alternatively , R2 and R3 come together , in combi 
nation with the carbon atoms to which they are attached , to 
form a 5-6 membered heterocycloalkyl or a C6-10 aryl ; [ 0077 ] R4 is selected from the group consisting of H , OH , 
and C1-4 alkoxy ; [ 0078 ] RS is selected from the group consisting of H , halo , 
C1-4 alkoxy , and phenoxy ; and [ 0079 ] Ró is selected from the group consisting of H and 
oxo ; or [ 0080 ] a compound of Formula IIIa : 
IIIa 
12 - R2 
R ! 
or a pharmaceutically acceptable salt thereof , wherein : 
[ 0081 ] L is selected from the group consisting of a bond , 
NH , N ( C1-4 alkyl ) , C2-4 alkynyl , NHC ( O ) ( C - 4 thioalkyl ) , 
C1-6 alkyleneoxy , 5-6 membered heterocycloalkyl , NHC 
( 0 ) C1-4 alkylene , and ( C1-4 alkylene ) -NHC ( O ) - ( C1-4 
alkylene ) - , wherein the C1-6 alkyleneoxy is further option 
ally substituted by one OH group ; [ 0082 ] Rla is selected from the group consisting of H , C1-4 
alkyl , C2-4 alkenyl , C1-4 cyanoalkylene , 5-6 membered het 
erocycloalkyl , 5-6 membered heteroaryl , NH ( C - 4 alkyl ) , 
and NH ( C2-4 alkenyl ) , wherein the C1-4 alkyl and C2-4 
alkenyl are each optionally substituted by one substituent 
selected from the group consisting of phenyl and hydroxy 
phenyl , and wherein the 5-6 membered heterocycloalkyl and 
5-6 membered heteroaryl are each optionally substituted by 
1 or 2 substituents independently selected from the group 
consisting of C1-4 alkyl , NH , and di - halo substituted phenyl ; [ 0083 ] L ’ is selected from the group consisting of a bond 
and 5-6 membered heterocycloalkyl ; and 
[ 0084 ] R24 is selected from the group consisting of H , C1-4 
hydroxyalkyl , -SO_C1-4 alkyl ) . 
[ 0085 ] In some embodiments , the cell is a eukaryotic cell 
or a cyanobacteria . In some embodiments , the cell is 
selected from the group consisting of an algal cell , a 
drosophila cell , a yeast cell , or a fungus cell . In some 
embodiments , the cell is an algal cell . In some embodiments , 
the cell is selected from the group consisting of : [ 0086 ] Chlamydomonas reinhardtii ; 
[ 0087 ] Chlorella sorokiniana ; [ 0088 ] Tetrachlorella alterans ; [ 0089 ] C. protothecoides ; 
[ 0090 ] C. vulgaris ; and [ 0091 ] Nannochloropsis sp . 
[ 0092 ] In some embodiments , the increasing lipid produc tion comprises increasing fatty acid production . In some 
embodiments , the increasing lipid production comprises increasing polyunsaturated fatty acid production . In some 
embodiments , the increasing lipid production comprises 
increasing triacylglycerol production . In some embodi 
ments , the increasing lipid production comprises increasing 
fatty acid production and increasing triacylglycerol produc 
tion . In some embodiments , the increasing lipid production 
comprises increasing polyunsaturated fatty acid production 
and increasing triacylglycerol production . 
[ 0093 ] In some embodiments , the method further com 
prises increasing carbohydrate accumulation in the cell . In 
some embodiments , the method further comprises increas ing carbohydrate production in the cell . 
[ 0094 ] In some embodiments , the lipid production is 
increased by greater than about 1.5 fold as compared to a cell 
that has not been contacted by the compound . In some 
embodiments , the lipid production is increased by greater 
than about 2 fold as compared to a cell that has not been 
contacted by the compound . In some embodiments , the lipid 
production is increased by greater than about 2.5 fold as 
compared to a cell that has not been contacted by the 
compound . 
[ 0095 ] In some embodiments , the contacting the cell with 
the compound does not reduce the rate of cellular growth 
compared to a cell that has not been contacted by the 
compound . In some embodiments , contacting the cell with 
the compound does not reduce the rate of photosynthesis of 
the cell compared to a cell that has not been contacted by the 
compound . In some embodiments , the contacting does not 
adversely affect the viability of the cell . 
[ 0096 ] In some embodiments , the lipid production is 
increased without exposing the cell to environmental stress . 
In some embodiments , the environmental stress comprises 
nutrient deprivation . In some embodiments , the environ 
mental stress comprises depriving the cell of nitrogen , 
depriving the cell of sulfur , depriving the cell of metal , or 
any combination thereof . In some embodiments , the envi 
ronmental stress comprises depriving the cell of nitrogen , 
depriving the cell of sulfur , depriving the cell of metal , or 
any combination thereof . 
[ 0097 ] The present application further provides a method 
of increasing lipid accumulation in a cell , comprising con 
tacting the cell with an effective amount of a compound 
selected from the group of compounds provided in Table 1A , 
Table 1B , Table 1C , Table 2A , Table 3A , Table 4 , Table 5 , 
and Table 6 , or a pharmaceutically acceptable salt thereof . 
[ 0098 ] The present application further provides a method 
of increasing lipid production in a cell , comprising contact 
ing the cell with an effective amount of a compound selected 
from the group provided in Table 1A , Table 1B , Table 1C , 
Table 2A , Table 3A , Table 4 , Table 5 , and Table 6 , or a 
pharmaceutically acceptable salt thereof . 
[ 0099 ] The present application further provides a method 
of increasing lipid accumulation in a cell , comprising con 
tacting the cell with an effective amount of a compound 
selected from the group provided in Table 4 , Table 5 , and 
Table 6 , or a pharmaceutically acceptable salt thereof . 
[ 0100 ] In some embodiments , the compound is selected 
from the group consisting of : 
[ 0101 ] ( 2- ( 3,4 - dimethoxyphenyl ) -N - methyl - N- (4 - ni 
trobenzyl ) ethan - 1 - amine ) ; 
[ 0102 ] ( 4 - ( ( 4- ( 2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ) ; and 
[ 0103 ] ( 3- ( adamantan - 1 - yl ( methyl ) amino ) propanenitrile ; 
[ 0104 ] or a pharmaceutically acceptable salt thereof . 
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[ 0105 ] In some embodiments , the compound is selected from the group consisting of : [ 0106 ] ( 2- ( 3,4 - dimethoxyphenyl ) -N - methyl - N- ( 4 - ni 
trobenzyl ) ethan - 1 - amine ) ; 
[ 0107 ] ( 4 - ( [ 4- ( 2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ) ; and 
[ 0108 ] ( 3- ( adamantan - 1 - yl ( methyl ) amino ) propanenitrile 
hydrochloride ) . 
[ 0109 ] In some embodiments , the cell is a eukaryotic cell 
or a cyanobacteria . In some embodiments , the cell is 
selected from the group consisting of an algal cell , a 
drosophila cell , a yeast cell , or a fungus cell . In some 
embodiments , the cell is an algal cell . In some embodiments , 
the cell is selected from the group consisting of : 
[ 0110 ] Chlamydomonas reinhardtii ; 
[ 0111 ] Chlorella sorokiniana ; 
[ 0112 ] Tetrachlorella alterans ; [ 0113 ] C. protothecoides ; 
[ 0114 ] C. vulgaris , and 
[ 0115 ] Nannochloropsis sp . 
[ 0116 ] In some embodiments , the increasing lipid accu 
mulation comprises increasing fatty acid accumulation . In 
some embodiments , the increasing lipid accumulation com prises increasing polyunsaturated fatty acid accumulation . In 
some embodiments , the increasing lipid accumulation com 
prises increasing triacylglycerol accumulation . In some 
embodiments , the increasing lipid accumulation comprises increasing fatty acid accumulation and increasing triacyl 
glycerol accumulation . In some embodiments , the increas ing lipid accumulation comprises increasing polyunsatu 
rated fatty acid accumulation and increasing triacylglycerol 
accumulation . 
[ 0117 ] In some embodiments , the method further com 
prises increasing carbohydrate accumulation in the cell . In 
some embodiments , the method further comprises increas ing carbohydrate production in the cell . 
[ 0118 ] In some embodiments , the lipid accumulation is increased by greater than about 1.5 fold as compared to a cell 
that has not been contacted by the compound . In some 
embodiments , the lipid accumulation is increased by greater 
than about 2 fold as compared to a cell that has not been 
contacted by the compound . In some embodiments , the lipid 
accumulation is increased by greater than about 2.5 fold as 
compared to a cell that has not been contacted by the 
compound . 
[ 0119 ] In some embodiments , the contacting the cell with 
the compound does not reduce the rate of cellular growth 
compared to a cell that has not been contacted by the 
compound . 
[ 0120 ] In some embodiments , contacting the cell with the 
compound does not reduce the rate of photosynthesis of the 
cell compared to a cell that has not been contacted by the 
compound . In some embodiments , the contacting does not 
adversely affect the viability of the cell . In some embodi 
ments , the lipid accumulation is increased without exposing 
the cell to environmental stress . In some embodiments , the 
environmental stress comprises nutrient deprivation . In 
some embodiments , the environmental stress comprises 
depriving the cell of nitrogen , depriving the cell of sulfur , 
depriving the cell of metal , or any combination thereof . [ 0121 ] The present application further provides a method 
of increasing lipid production in a cell , comprising contact 
ing the cell with an effective amount of a compound selected 
from the group provided in Table 4 , Table 5 , and Table 6 , or 
a pharmaceutically acceptable salt thereof . 
[ 0122 ] In some embodiments , the compound is selected from the group consisting of : [ 0123 ] ( 2- ( 3,4 - dimethoxyphenyl ) -N - methyl - N- ( 4 - ni 
trobenzyl ) ethan - 1 - amine ) ; [ 0124 ] ( 4-4-2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ) ; and 
[ 0125 ] ( 3- ( adamantan - 1 - yl ( methyl ) amino ) propanenitrile ; [ 0126 ] or a pharmaceutically acceptable salt thereof . [ 0127 ] In some embodiments , the compound is selected 
from the group consisting of : [ 0128 ] ( 2- ( 3,4 - dimethoxyphenyl ) -N - methyl - N- ( 4 - ni 
trobenzyl ) ethan - 1 - amine ) ; [ 0129 ] ( 4 - ( ( 4- ( 2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ) ; and 
[ 0130 ] ( 3- ( adamantan - 1 - yl ( methyl ) amino ) propanenitrile hydrochloride ) . 
[ 0131 ] In some embodiments , the cell is a eukaryotic cell 
or a cyanobacteria . In some embodiments , the cell is 
selected from the group consisting of an algal cell , a 
drosophila cell , a yeast cell , or a fungus cell . In some 
embodiments , the cell is an algal cell . In some embodiments , 
the cell is selected from the group consisting of : [ 0132 ] Chlamydomonas reinhardtii ; 
[ 0133 ] Chlorella sorokiniana ; 
[ 0134 ] Tetrachlorella alterans ; [ 0135 ] C. protothecoides ; 
[ 0136 ] C. vulgaris , and 
[ 0137 ) Nannochloropsis sp . 
[ 0138 ] In some embodiments , the increasing lipid produc 
tion comprises increasing fatty acid production . In some 
embodiments , the increasing lipid production comprises 
increasing polyunsaturated fatty acid production . In some 
embodiments , the increasing lipid production comprises 
increasing triacylglycerol production . In some embodi 
ments , the increasing lipid production comprises increasing 
fatty acid production and increasing triacylglycerol produc 
tion . In some embodiments , the increasing lipid production 
comprises increasing polyunsaturated fatty acid production 
and increasing triacylglycerol production . 
[ 0139 ] In some embodiments , the method further com 
prises increasing carbohydrate accumulation in the cell . In 
some embodiments , the method further comprises increas ing carbohydrate production in the cell . 
[ 0140 ] In some embodiments , the lipid production is 
increased by greater than about 1.5 fold as compared to a cell 
that has not been contacted by the compound . In some 
embodiments , the lipid production is increased by greater 
than about 2 fold as compared to a cell that has not been 
contacted by the compound . In some embodiments , the lipid 
production is increased by greater than about 2.5 fold as 
compared to a cell that has not been contacted by the 
compound . 
[ 0141 ] In some embodiments , the contacting the cell with 
the compound does not reduce the rate of cellular growth 
compared to a cell that has not been contacted by the 
compound . In some embodiments , contacting the cell with 
the compound does not reduce the rate of photosynthesis of 
the cell compared to a cell that has not been contacted by the 
compound . In some embodiments , the contacting does not 
adversely affect the viability of the cell . [ 0142 ] In some embodiments , the lipid production is 
increased without exposing the cell to environmental stress . 
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In some embodiments , the environmental stress comprises 
nutrient deprivation . In some embodiments , the environ 
mental stress comprises depriving the cell of nitrogen , 
depriving the cell of sulfur , depriving the cell of metal , or 
any combination thereof . 
[ 0143 ] Unless otherwise defined , all technical and scien 
tific terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which this 
invention belongs . Methods and materials are described 
herein for use in the present invention ; other , suitable 
methods and materials known in the art can also be used . 
The materials , methods , and examples are illustrative only 
and not intended to be limiting . All publications , patent 
applications , patents , sequences , database entries , and other 
references mentioned herein are incorporated by reference in 
their entirety . In case of conflict , the present specification , 
including definitions , will control . 
DESCRIPTION OF DRAWINGS 
[ 0144 ] FIG . 1 shows EC 250 ( UM ) values and microscopy images of compounds 1 , 62 , and 136 in Chlamydomonas 
reinhardtii cells . 
[ 0145 ] FIGS . 2A - 2C show algal cell growth over a period 
of 72 hours in the presence of compound 1 ( FIG . 2A ) , 
compound 62 ( FIG . 2B ) , and compound 136 ( FIG . 2C ) . 
[ 0146 ] FIG . 3 shows increased lipid accumulation in cells in the presence of compounds 1 , 62 , and 136 . 
[ 0147 ] FIG . 4 shows increased lipid accumulation in cells 
over 72 hours in the presence of compounds 1 , 62 , and 136 . [ 0148 ] FIG . 5 shows increased fatty acid levels in cells in 
the presence of compounds 1 , 62 , and 136 . 
[ 0149 ] FIG . 6 shows increased triacylglyercol levels in 
cells in the presence of compounds 1 , 62 , and 136 . 
[ 0150 ] FIG . 7 shows the levels of chlorophyll A ( Chl A ) , 
chlorophyll B ( Chl B ) and carotenoid in cells in the presence 
of compounds 1 , 62 , and 136 . 
[ 0151 ] FIG . 8 shows the cellular effects of compounds 1 , 
62 , and 136 on the levels of proteins required for photosyn 
thesis . 
[ 0152 ] FIG . 9 shows increased carbohydrate levels in cells in the presence of compounds 1 , 62 , and 136 . 
[ 0153 ] FIG . 10 shows the effect of compounds 1 , 62 , and 
136 on the total level of proteins in cells . 
[ 0154 ] FIGS . 11A - 11C show growth of various algal spe 
cies in the presence of compound 1 ( FIG . 11A ) , compound 
62 ( FIG . 11B ) , and compound 136 ( FIG . 11C ) . [ 0155 ] FIGS . 12A - 12C show lipid body accumulation in C. reinhardtii cells using representative compounds of For 
mula Ia ( FIG . 12A ) , Formula Ila ( FIG . 12B ) , and Formula 
IIIa ( FIG . 12C ) . Nile red fold - change values in the primary 
screening experiment at 10 uM final compound concentra 
tion ( i ) and Nile red fold - change values in the confirmatory 
screen at 10 um compound concentration ( ii ) are provided 
for each compound . The scale bar of each image represents 
mercialization due to high costs in producing and processing 
sufficient biomass given the primitive state of knowledge of 
algal biology and biotechnology ( see , e.g. , Singh et al . , 
Bioresource Technology , 2011 , 102 , 26-34 and Hannon et 
al . , Biofuels , 2010 , 1 , 763-784 ) . 
[ 0157 ] Algae are a diverse group of microorganisms that 
include species that inhabit marine , freshwater and terres 
trial niches . It is estimated that 30-50 % of the net photo 
synthetic productivity on plant earth is contributed by phy 
toplankton including algae . Yet , our understanding of the 
biology , metabolism and genetics of any algal species is 
limited . Among the microalga , Chlamydomonas reinhardtii , is widely employed as a model organism . Chlamydomonas is capable of harnessing light and fixing Co , to produce 
structural and energy rich storage compounds , including 
carbohydrates , lipids , and proteins . Desirable characteristics 
for use of algae as a biofuel feedstock include : rapid growth 
rate , high lipid product content , tolerance to variable envi 
ronmental conditions , such as poor water quality , high 
salinity , extremes of pH , resistance to pathogens , ability to 
compete for micronutrients , and ease of harvesting and 
extraction ( see e.g. , Hannon et al . , Biofuels , 2010 , 1 , 763 
784 , Chisti , Y. Biotechnology Advances , 2007 , 25 , 294-306 , 
and Deng et al . , Biomass and Bioenergy , 2011 , 35 , 1811 
1817 ) . All of these factors may not be realized in one algal 
species but understanding the factors that enhance or limit , for example , biomass accumulation in a model organism 
such as Chlamydomonas will ultimately increase our ability 
to select and / or generate strains with enhanced traits useful for biofuel production . 
[ 0158 ] Conditions currently employed to induce lipid 
accumulation in algae require an environmental stress , par 
ticularly nutrient deprivation of nitrogen , sulphur , or some 
metal ( see , e.g. , Deng et al . , Biomass and Bioenergy , 2011 , 
35 , 1811-1817 ; Gamier et al . , Journal of Proteomics , 2014 , 
105 , 107-120 ; and Msanne et al . , Phytochemistry , 2012 , 75 , 
50-59 ) . Nutrient limitation may be achieved during normal 
growth when cultures reach saturation density . For example , 
nitrogen may become limiting at this time and triglyceride 
rich lipid droplets will become visible and measurable ( see 
e.g , Msanne et al . , Phytochemistry , 2012 , 75 , 50-59 and 
Wase et al . , Journal of Proteome Research , 2014 , 13 , 
1373-1396 ) . However , this may be commensurate with 
cessation of protein synthesis , bleaching of the cultures as 
the chlorophylls are degraded , depletion of the photosyn 
thetic enzymes such as RuBisCO , and turnover of mem brane lipids , including thylakoid lipids ( see , e.g. , Wase et al . , 
Journal of Proteome Research , 2014 , 13 , 1373-1396 ) . What 
is desired are methods to activate metabolic pathways lead ing to storage of lipids without diversion of carbon and 
nitrogen away from other anabolic processes required for 
cell growth and division . 
[ 0159 ] Accordingly , the present application provides 
methods of increasing lipid accumulation and production in 
cells ( e.g. , algal cells ) using activators of lipid synthesis and 
storage provided herein . 
5 um . 
DETAILED DESCRIPTION 
Compounds ( 0156 ] There are several advantages to employing algae for the production of biofuels , for example , high productiv 
ity due to rapid growth and the ability to accumulate lipid to 
20-40 % dry weight and potentially 100 - fold more oil per 
acre than soybeans or other oil - seed bearing plants . How 
ever , at the present time algal oils are not ready for com 
[ 0160 ] The present application provides compounds that 
are activators of lipid synthesis and lipid storage in cells . In 
some embodiments , the compound is a compound of For 
mula I : 
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TABLE 1 - continued 
Substituents of Formula I 
R ] NO2 
N R1 = 
R ! * R4 
RS 
R1 = or a pharmaceutically acceptable salt thereof , wherein : 
[ 0161 ] substituents R " , R ?, R3 , R4 , and RS of Formula I are 
as defined herein . ax 
das R1 = 
R = = woon 
[ 0162 ] In some embodiments , a compound of Formula I is 
substituted according to the substituents provided in Table 1 . 
In some embodiments , each R ' , R² , R3 , R1 , and RS , unless 
specified otherwise in Table 1 , is selected from the group 
consisting of H , OH , SH , CN , NO ,, halo , oxo , C1-6 alkyl , 
C2-6 alkenyl , C2-6 alkynyl , C1-6 haloalkyl , C1-6 cyanoalkyl , 
C1-6 hydroxyalkyl , C1-6 alkoxy , ( C1-6 alkyl ) - ( C1-6 alkoxy ) , 
- ( C - 6 alkoxy ) - ( C ) - alkoxy ) , C- . haloalkoxy , C3-10 
cycloalkyl , Co - 10 aryl , 5-10 membered heteroaryl , 4-10 
membered heterocycloalkyl , amino , C1-6 alkylamino , 
di ( C1-6 alkyl ) amino , carbamyl , C1-6 alkylcarbamyl , di ( C1-6 
alkyl ) carbamyl , carbamoyl , C1-6 alkylcarbamoyl , di ( C1-6 
alkyl ) carbamoyl , C. alkylcarbonyl , Cl- , alkoxycarbonyl , 
C1-6 alkylcarbonylamino , C1-6 alkylsulfonylamino , amino 
sulfonyl , C1-6 alkylaminosulfonyl , di ( C1-6 alkyl ) aminosul fonyl , aminosulfonylamino , C - 6 alkylaminosulfonylamino , 
di ( C1-6 alkyl ) aminosulfonylamino , aminocarbonylamino , 
C1-6 alkylaminocarbonylamino , and di ( C1-6 alkyl ) aminocar 
bonylamino . In some embodiments , each R² , R2 , R3 , R4 , RS , 
R® , and R ’ , unless specified otherwise in Table 1 , is H. In 
some embodiments , at least one of R1 , R2 , R3 , R4 , and RS is 
not H. 
[ 0163 ] It is understood that the me and 
shown in the substituent groups provided in Tables 
1-6 represent the point of attachment between the represen 
tative Formula ( e.g. , Formula 1 , Formula II , or Formula III ) 
and the substituent group . 
N 
R1 = 
N 
R = 
TABLE 1 
Substituents of Formula I R1 = on 
F 
R1 = 
R = w 
R1 = 
R = orot CI 
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TABLE 1 - continued TABLE 1 - continued 
Substituents of Formula I Substituents of Formula I 
R 
Ri = 
R1 
R3 = 
IZ 
R 
R & R3 = 
R1 = 
wherein : 
refers to the bond 
connecting Ri to Formula 1 ; and 
w refers to the bond 
connecting R3 to Formula I 
R ! N 
R2 = CH3 R3 = 
F. 
R3 = 
R4 OMe F 
R1 = CH3 
R1 = tal OH R3 OS 
R1 = N 
R = ox 
want mox R1 = 
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TABLE 1 - continued TABLE 1 - continued 
Substituents of Formula I Substituents of Formula I 
N HN 
R1 xor Ri = N 
R1 = 
F R 
RS = C1 
S 
R1 = ost impan R ! 
R2 
R1 = 
OH 
oro R1 ray R1 = 
R1 = impun 
Ri = 007 
2 
R = uxo 
Box 
-Xy 
R = 
Br 
# R1 = 
US 2020/0071735 A1 Mar. 5 , 2020 
10 
TABLE 1 - continued TABLE 1 - continued 
Substituents of Formula I Substituents of Formula I 
R5 = Hoa O = DOR2 = R3 = IZ 
R4 = SCH2CH3 
R3 = OCHZ R2 = 
R4 = 
RS = 
orix 
omt R4 = R3 = 
ta 
oy 
oy 
..ta 
out 
NH R1 = ho NH 
R = CH3 
R3 = mulin NH 
Br RS Bu 
R5 = R = _CH3 
R3 
toto 
** tono NH 
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TABLE 1 - continued 
Substituents of Formula I 
F 
E 
R1 = 
F F 
R2 = 
for 
R = _C1 
CH2 Ri = 
or a pharmaceutically acceptable salt thereof , wherein : [ 0165 ] L is selected from the group consisting of a bond , 
C1-4 alkylene , C1-4 hydroxyalkylene , C1-4 alkyleneoxy , ( C - 4 alkylene ) -NR2– ( C1-4 alkylene ) , - , CEO ) , and 
CEO ) NH ; [ 0166 ] RP is selected from the group consisting of H and 
methyl ; 
[ 0167 ] Ris H or C -4 alkoxy ; [ 0168 ] R * is selected from the group consisting of H and piperidinyl ; 
[ 0169 ] Cyl is selected from the group consisting of phe 
nyl , C3-8 cycloalkyl , 4-6 membered heterocycloalkyl , and 
4-10 membered heteroaryl ; [ 0170 ] Rºy is selected from the group consisting of halo , 
C1-4 alkyl , C1-4 alkoxy , phenyl , ( C1-4 alkylene ) - ( phenyl ) , 
C3-10 cycloalkyl , and ( C1-4 alkylene ) - ( C3-10 cyloalkyl ) , 
wherein each phenyl and the phenyl group of — ( C1-4 
alkylene ) - ( phenyl ) is optionally substituted by 1 or 2 sub 
stituents independently selected from the group consisting of 
OH , halo , C1-4 alkyl , and C1-4 alkoxy ; 
[ 0171 ] n is 0 or 1 ; and 
[ 0172 ] p is 0 , 1 , 2 , 3 , 4 , or 5 . 
[ 0173 ] In some embodiments , L is selected from the group 
consisting of a bond , CH ( OH ) CH 
CH , CH , NR'CH , , CH , NR'CH , CH , 
OCH2CH2CH2CH2 CHINH , CO ), and 
CEO ) NH . In some embodiments , L is selected from the 
group consisting of a bond , CH , CH ( OH ) CH , 
CH_CH_NHCH , — CH_N ( CH3 ) CH CH2 
OCH CH CH CH , — , CH_NH , CO ), and 
C = O ) NH . In some embodiments , L is CH2 . [ 0174 ] In some embodiments , R3 is selected from the 
group consisting of H and methoxy . In some embodiments , 
R is H. In some embodiments , Rº is methoxy . [ 0175 ] In some embodiments , R4 is H. In some embodi 
ments , R4 is piperidinyl . 
[ 0176 ] In some embodiments , Cy ' is phenyl . In some 
embodiments , Cyl is C3.8 cycloalkyl . In some embodiments , 
Cy ' is C5-8 cycloalkyl . In some embodiments , Cy ' is a C3-8 
cycloalkyl selected from the group consisting of cyclopen 
tyl , cyclohexyl , and cycloheptyl . In some embodiments , Cyl 
is a 4-6 membered heterocycloalkyl . In some embodiments , 
Cyl is a 4-6 membered heterocycloalkyl selected from the 
group consisting of piperazinyl , and morpholinyl . In some 
embodiments , Cyl is piperazinyl . In some embodiments , 
Cyl is a 4-10 membered heteroaryl . In some embodiments , 
Cyl is a 4-6 membered heteroaryl . In some embodiments , 
Cyl is an 8-10 membered heteroaryl . In some embodiments , 
Cy ' is a 4-10 membered heteroaryl selected from the group 
consisting of : 
F mafuri R1 = 
F F 
F 
Rg = _OCHZ 
NH 
" xi , & 
xila R5 = CI 
[ 0164 ] The present application further provides a com 
pound of Formula Ia : oot to 
Ia 
R ? ( R ) NO2 [ 0177 ] In some embodiments , Rºy is selected from the group consisting of halo , C - 4 alkyl , C -4 alkoxy , phenyl , 
CH - ( phenyl ) , C5-7 cycloalkyl , and ( CH2 ) - ( C5-7 
cycloalkyl ) . In some embodiments , R Cy is selected from the group consisting of fluoro , methyl , 2 - butyl , methoxy , phe 
nyl , CH2- ( phenyl ) , cyclopentyl , cycloheptyl , 
R4 
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and 
optionally substituted by 1 or 2 substituents independently 
selected from the group consisting of OH , fluoro , bromo , 
methyl , methoxy , ethoxy , and butoxy . 
[ 0179 ] In some embodiments , n is 0. In some embodi 
ments , n is 1. In some embodiments , p is 1 , 2 , or 3. In some 
embodiments , p is 3 , 4 , or 5. In some embodiments , p is 1 
or 2. In some embodiments , p is 1. In some embodiments , p 
is 2. In some embodiments , p is 3. In some embodiments , p 
is 4. In some embodiments , p is 5 . 
[ 0180 ] In some embodiments , the compound of Formula la is selected from the group of compounds provided in 
Table 1A . 
[ 0178 ] wherein each phenyl and the phenyl group of 
CH2- ( phenyl ) is optionally substituted by 1 or 2 substitu 
ents independently selected from the group consisting of 
OH , halo , C1-4 alkyl , and C1-4 alkoxy . In some embodiments , 
each phenyl and the phenyl group of CH2- ( phenyl ) is 
TABLE 1A 
NO2 ( 1 ) 
NO2 ( 29 ) 
F 
NO2 ( 31 ) 
N 
OH 
( 40 ) 
NO2 mad 
NO2 ( 6 ) 
ON ( 15 ) 
O2N . ( 28 ) 
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TABLE 1A - continued 
NO2 ( 14 ) 
( 43 ) 
NO2 
( 3 ) 
NO2 
( 9 ) 
NO2 
F 
NO2 ( 33 ) 
' N 
cora NO2 
NO2 ( 12 ) 
NO2 ( 19 ) 
( 41 ) 
NO2 
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TABLE 1A - continued 
( 42 ) gora NO2 
NO2 ( 32 ) 
( 13 ) 
NO2 
N 
( 27 ) 
NO2 
( 8 ) 
NO2 
( 36 ) 
dora 
ma 
orang 
amo 
O2N 
NO2 ( 20 ) 
NO2 ( 21 ) 
oo 
( 4 ) 
NO2 
N 
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TABLE 1A - continued 
( 59 ) 
NO2 
F 
NH 
F 
( 16 ) 
NO2 
N 
( 26 ) 
N 
ON 
( 22 ) 
and 
NO2 
?? . ( 34 ) 
N 
O2N Br 
or a pharmaceutically acceptable salt thereof . In some 
embodiments , the pharmaceutically acceptable salt is a hydrochloride salt . 
[ 0181 ] In some embodiments , provided herein is a com 
pound of Formula Ib : 
Ib 
NO2 
nyl and the phenyl group of ( C1-4 alkylene ) - ( phenyl ) is 
optionally substituted by 1 or 2 substituents independently 
selected from the group consisting of OH , halo , C -4 alkyl , 
and C1-4 alkoxy . 
[ 0186 ] In some embodiments , L is a bond . In some 
embodiments , L is CH2 . In some embodiments , L is CEO ) . 
In some embodiments , L is CH ( OH ) CHZ .
[ 0187 ] In some embodiments , R4 is H. In some embodi 
ments , R4 is piperidinyl . In some embodiments , RCY is 
selected from the group consisting of C1-4 alkyl , phenyl , 
CH2- ( phenyl ) , C5-7 cycloalkyl , and ( CH2 ) ( C5-7 
cycloalkyl ) , wherein each phenyl and the phenyl group of 
CH2- ( phenyl ) is optionally substituted by 1 or 2 substitu 
ents independently selected from the group consisting of 
OH , halo , C1-4 alkyl , and C -4 alkoxy . In some embodiments , 
RCY is selected from the group consisting of methyl , 2 - butyl , 
phenyl , -CH2- ( phenyl ) , cyclopentyl , cycloheptyl , 
R4 
or a pharmaceutically acceptable salt thereof , wherein , L , 
R + , and Rºy are as defined above for compounds of Formula 
Ia . 
[ 0182 ] In some embodiments , the compound is a com 
pound of Formula Ib , or a pharmaceutically acceptable salt 
thereof , wherein : 
[ 0183 ] L is selected from the group consisting of a bond , C - 4 alkylene , C - 4 hydroxyalkylene , and CEO ) ; 
[ 0184 ] R4 is selected from the group consisting of H and piperidinyl ; and 
[ 0185 ] Rºy is selected from the group consisting of C1-4 
alkyl , phenyl , ( C1-4 alkylene ) - ( phenyl ) , C3-10 cycloalkyl , 
and – ( C1-4 alkylene ) - ( C3-10 cyloalkyl ) , wherein each phe 
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[ 0188 ] wherein each phenyl and the phenyl group of 
CH2- ( phenyl ) is optionally substituted by 1 or 2 substitu 
ents independently selected from the group consisting of 
OH , halo , C -4 alkyl , and C -4 alkoxy . In some embodiments , 
each phenyl and the phenyl group of CH2- ( phenyl ) is 
optionally substituted by 1 or 2 substituents independently 
selected from the group consisting of OH , fluoro , bromo , 
methyl , methoxy , ethoxy , and butoxy . 
[ 0189 ] In some embodiments , the compound of Formula 
Ib is selected from the group of compounds provided in 
Table 1B . 
TABLE 1B 
NO2 ( 29 ) 
F 
( 26 ) 
O2N 
NO2 ( 31 ) 
OH 
( 40 ) 
NO2 
N 
NO2 ( 6 ) 
O2N . ( 15 ) 
O2N . ( 28 ) 
( 43 ) 
* NO2 
( 9 ) 
NO2 
F 
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TABLE 1B - continued 
NO2 ( 33 ) 
N 
NO2 
( 41 ) 
NO2 
( 42 ) 
cora NO2 
NO2 ( 32 ) 
( 13 ) 
NO2 
N 
( 27 ) 
NO2 
( 8 ) 
dora 
maana 
dao 
NO2 
( 4 ) 
NO2 
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TABLE 1B - continued 
( 16 ) 
NO2 and N 
HO . ( 34 ) 
N 
O2N Br 
a 
or a pharmaceutically acceptable salt thereof . In some 
embodiments , the pharmaceutically acceptable salt is a 
hydrochloride salt . 
[ 0190 ] The present application further provides a com 
pound of Formula Ic : 
Ic 
NO2 
R32 
-Rta 
[ 0200 ] In some embodiments , L4 is selected from the 
group consisting of bond , S , C ( O ) NH , 
OCH2CH2OCH2CH2 and SO2 - Cy2 - Cy » . In some 
embodiments , L4 is a bond . In some embodiments , L * is S. 
In some embodiments , L4 is CEO ) NH . In some embodi 
ments , L * is C -6 alkyleneoxy . In some embodiments , Lº is 
OCH_CH_OCH , CH , — . In some embodiments , L4 is SO2 - Cy - Cys . In some embodiments , Cy is a 6 - membered heterocycloalkyl group comprising two ring heteroatoms 
which are nitrogen . In some embodiments , Cy2 is piperazi 
nyl . In some embodiments , Cy3 is a 6 - membered heterocy 
cloalkyl group comprising one ring heteroatom which is 
nitrogen . In some embodiments , Cy3 is piperidinyl . 
[ 0201 ] In some embodiments , R4a is H. In some embodi 
ments , L4 is a bond and R44 is H. In some embodiments , R4 is C -4 alkyl . In some embodiments , R * is methyl . In some 
embodiments , L4 is a bond and R4a is methyl . In some 
embodiments , R40 is ( C - 4 alkylene ) - ( C3-6 cycloalkyl ) . In 
some embodiments , R44 is – ( CH2CH2 )- ( C5-6 cycloalkyl ) . 
In some embodiments , R4a is ( CH2CH2 ) - ( cyclohexyl ) . In 
some embodiments , R4a is a 5-6 membered heterocyloalkyl 
group comprising one ring heteroatom which is nitrogen and 
one ring heteroatom which is oxygen . In some embodi 
ments , R4a is morpholinyl . In some embodiments , R4a is ( C1-4 alkylene ) - ( phenyl ) . In some embodiments , R4a is ( CH2 ) - ( phenyl ) . 
[ 0202 ] In some embodiments , the compound of Formula 
Ic is selected from the group of compounds provided in 
Table 1C . 
4a or a pharmaceutically acceptable salt thereof , wherein : [ 0191 ] L is selected from the group consisting of a bond 
and C ( O ) NH ; [ 0192 ] R3a is selected from the group consisting of H , C1-4 
alkyl , C -4 alkoxy , -phenyl- ( C1-4 alkylene ) -R " , - ( phenyl ) 
SO_R® , and 5-6 membered heteroaryl , wherein the 5-6 
membered heteroaryl is optionally substituted with a C1-4 
alkyl group ; [ 0193 ] R is selected from the group consisting of 5-6 
membered heteroaryl and 5-6 membered heterocycloalkyl , 
wherein the 5-6 membered heterocycloalkyl is optionally 
substituted by a C1-4 alkyl group ; [ 0194 ] L * is selected from the group consisting of a bond , 
S , CEO ) NH , C1-6 alkyleneoxy , and SO2 - Cy2 - Cys ; [ 0195 ] Cy- and Cy are each an independently selected 5-6 
membered heterocycloalkyl group ; and [ 0196 ] R a is selected from the group consisting of H , C1-4 
alkyl , ( C1.4 alkylene ) - ( Cz . , cycloalkyl ) , 5-6 membered 
heterocyloalkyl , and C1-4 alkylene ) - ( phenyl ) . 
[ 0197 ] In some embodiments , L is a bond . In some 
embodiments , L ’ is C ( O ) NH . [ 0198 ] In some embodiments , R3a is H. In some embodi 
ments , L ’ is a bond and R3a is H. 
[ 0199 ] In some embodiments , R3a is C1-4 alkoxy . In some 
embodiments , R3a is methoxy . In some embodiments , L is 
a bond and R3a is methoxy . In some embodiments , R3a is 
-phenyl- ( C1-4 alkylene ) -R . In some embodiments , R3a is 
-phenyl- ( CH2 )-R . In some embodiments , R3a is - ( phe 
nyl ) -SO , R " . In some embodiments , R ' is selected from the 
group consisting of 5-6 membered heteroaryl and 5-6 mem 
bered heterocycloalkyl substituted by a C1-4 alkyl group . In 
some embodiments , R is selected from the group consisting 
of pyridyl and 4 - methylpiperidinyl . In some embodiments , 
R3a is a 5-6 membered heteroaryl substituted with a C1-4 
alkyl group . In some embodiments , R3a is 4 - tert - butylthiaz 
olyl . 
TABLE 1C 
( 50 ) 
NO2 aina N 
OCH3 ( 51 ) 
NO2 
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TABLE 1C - continued 
O2N . ( 52 ) 
NO2 ( 44 ) 
from the group consisting of H , OH , SH , CN , NO2 , halo , 
oxo , C1-6 alkyl , C2-6 alkenyl , C2-6 alkynyl , C - haloalkyl , 
C1-6 cyanoalkyl , C1-6 hydroxyalkyl , C1-6 alkoxy , — ( C1-6 
alkyl ) - ( C1-6 alkoxy ) , — ( C1-6 alkoxy ) - ( C1-6 alkoxy ) , C1-6 
haloalkoxy , C3-10 cycloalkyl , C6-10 aryl , 5-10 membered 
heteroaryl , 4-10 membered heterocycloalkyl , amino , C1-6 
alkylamino , di ( C - 6 alkyl ) amino , carbamyl , C- , alkylcar 
bamyl , di ( C1-6 alkyl ) carbamyl , carbamoyl , C1-6 alkylcar 
bamoyl , di ( C1-6 alkyl ) carbamoyl , C1-6 alkylcarbonyl , C1-6 
alkoxycarbonyl , C1-6 alkylcarbonylamino , C1-6 alkylsulfo 
nylamino , aminosulfonyl , C1-6 alkylaminosulfonyl , di ( C1-6 
alkyl ) aminosulfonyl , aminosulfonylamino , C1-6 alkylamino 
sulfonylamino , di ( C - 6 alkyl ) aminosulfonylamino , amin 
ocarbonylamino , C1-6 alkylaminocarbonylamino , and 
di ( C1-6 alkyl ) aminocarbonylamino . In some embodiments , 
each R ' , R ?, R , R4 , RS , Ró , and R ?, unless specified 
otherwise in Table 2 , is H. In some embodiments , at least 
one of R1 , R² , R3 , R4 , RS , Ró , and R ?, is not H. 
( 48 ) TABLE 2 
Substituents of Formula II 
and 
O2N . 
Ri = od 
( 49 ) R2 = OH 
NO2 
Ri = 
R1 = 
or a pharmaceutically acceptable salt thereof . In some 
embodiments , the pharmaceutically acceptable salt is a hydrochloride salt . 
[ 0203 ] The present application further provides a com 
pound of Formula II : 
Ri = 
II 
R7 R2 R2 = OHC3 
R ? & R4 = CH3 
RO 
R5 
R4 R1 = a 
R2 = OH 
R ] 
Ri = or a pharmaceutically acceptable salt thereof , wherein sub 
stituents R1 ,R2 , R3 , R4 , RS , R ' , and R7 of Formula II are as 
defined herein . 
[ 0204 ] In some embodiments , each R ' , R² , R3 , R4 , RS , R " , 
and R ?, unless specified otherwise in Table 2 , is selected 
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TABLE 2 - continued TABLE 2 - continued 
Substituents of Formula II Substituents of Formula II 
R. 
R2 & R3 = + To 
You 
R ? = OH 
wherein : 
refers to the bond 
connecting R2 to Formula II ; and 
w refers to the bond 
connecting R3 to Formula II 
Ri = 
R = F 
R = 
R 
R2 = C1 
R1 = 
R ? = benzyl 
R ? = OH 
R2 = benzyl 
R3 = NO2 
R ' = benzyl 
R ?, R4 , R = OCHZ 
R ? = phenyl 
R2 = 
R2 = CH3 
CI 
 OH 
R ? = F 
R ' = CH3 
R ? = isopropyl 
R1 and R2 = ethyl 
R ? = trans - cinnamyl 
R2 = OCH3 
R5 
R = 
R1 = 
R ? = NO2 
R = ethyl 
R ' = phenyl 
R = NO2 R1 = phenyl 
R ? = Br 
R ' = n - nitrophenyl 
R ? = _OCH CH3 
R1 = 
Ri = 
R2 = NO2 
R2 = _OCH2CH3 
Ri = 
Ri = 
R2 = C1 R2 = OH 
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TABLE 2 - continued TABLE 2 - continued 
Substituents of Formula II Substituents of Formula II 
R = R1 au F 
R2 = CH3 
R ?, R ?, and R ' = OCH3 
R = ( BO ) 
R1 = 
Ri = 
R2 = F 
R ? = NO2 
R ? = CH3 
R1 = 
R2 & R3 = 
R2 = NO2 
Ri = 
wherein : 
refers to the bond 
connecting Rºto Formula II ; and 
wur refers to the bond 
connecting R3 to Formula II 
R = ethyl 
R2 = N ( ethyl ) 2 
R ' = p - nitrophenyl 
R2 OCH2CH2CH2CH3 
R2 = CH3 
R = 
F R : 
R2 = _OCH CH3 
R ? = benzyl 
R = C1 
R ? = OH 
R = 
Ri = 
R ? = _OCH2CH3 
R7 = NO2 R1 = 
to R1 R2 = F R == CH2CH2OH R ? = isopropyl 
R1 CH2CH2OH 
R2 = ethyl 
R1 = benzyl 
R & R = OCH3 
R = CH CH OH 
R2 = CH3 
Ri = 
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TABLE 2 - continued TABLE 2 - continued 
Substituents of Formula II Substituents of Formula II 
NO2 
R1 = R1 = 
OH 
R1 = Ri = -N 
R2 = NO2 
R = 
R ? & R3 = 
Ri = 
wherein : 
refers to the bond 
connecting R2 to Formula II ; and 
un refers to the bond 
connecting R3 to Formula II 
R = 0 
R ? = OCH3 R ' = cyclohexyl 
R1 = 
R1 = 
F 
O2N 
R4 & R = _OCH3 
R ' = Br 
R7 = OH 
R = 
02N R1 = 
R ? & R3 = _OCH3 
R ? = Br 
R ? = OH 
R = 
O2N R ! 
R3 & R4 = _OCHZ 
R ? = NO2 
R ? = sec - butyl 
R2 = NO2 R = 
O2N 
R = 
R ? & R4 = _OCH3 
R = 
O2N 
R2 = NO2 
R ' = cyclophenyl 
R ? = NO2 
R ' = cyclophenyl 
R2 = NO2 
R ? = ethyl 
R ? = tert - butyl 
R = 0 
R7 = F 
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TABLE 2 - continued [ 0205 ] The present application further provides a com 
pound of Formula IIa : 
Substituents of Formula II 
Ila 
F 
R2 
R = 
R5 
R4 
N 
R1 = 
Rla R = 0 
R = N 
R = -OCH3 
or a pharmaceutically acceptable salt thereof , wherein : [ 0206 ] L ' is selected from the group consisting of a bond , C -4 alkylene , C2-4 alkenylene , C - 4 hydroxyalkylene , C. 
alkyleneoxy , 4-6 membered heterocycloalkylene , and 
CEO ) , wherein the C - 4 alkyleneoxy is further optionally 
substituted by one OH group ; [ 0207 ] Ra is selected from the group consisting of OH , C1-4 alkyl , C5-10 cycloalkyl , 8-10 membered heteroaryl , 
phenyl , - ( C1-4 alkylene ) - ( phenyl ) , and 10-13 membered heteroaryl , wherein the C5-10 cycloalkyl , phenyl , and the 
phenyl group of the ( C1-4 alkylene ) - ( phenyl ) are each 
optionally substituted by 1 , 2 , or 3 substituents indepen dently selected from the group consisting of halo , OH , NO2 , 
C -4 alkyl , and C -4 alkoxy , and wherein the 10-13 mem bered heteroaryl is optionally substituted by one halo group ; [ 0208 ] R² is selected from the group consisting of H , halo , 
OH , NO2 , C1-4 alkyl , C -4 alkoxy , and ( C1-4 alkylene ) - ( 8 
10 membered heteroaryl ) ; [ 0209 ] R ’ is selected from the group consisting of H , halo , 
C1-4 alkoxy , and phenoxy ; or [ 0210 ] alternatively , R2 and R come together , in combi 
nation with the carbon atoms to which they are attached , to 
form a 5-6 membered heterocycloalkyl or a C6-10 aryl ; [ 0211 ] R is selected from the group consisting of H , OH , 
and C1-4 alkoxy ; [ 0212 ] R?is selected from the group consisting of H , halo , 
C1-4 alkoxy , and phenoxy ; and [ 0213 ] R? is selected from the group consisting of H and 
R1 = 
2HCI mo 
od 
OH 
impan 
R1 = Br 
HCI 
N 
??? . 
Ri = 
NH 
[ 0214 ] In some embodiments , L ' is a bond . In some 
embodiments , L ' is a C1-4 alkylene . In some embodiments , 
L ' is selected from the group consisting of methylene and 
ethylene . In some embodiments , L ' is C2-4 alkenylene . In 
some embodiments , L ' is propenylene . In some embodi 
ments , L'is -CH2CH = CH— . In some embodiments , L ' is 
C1-4 hydroxyalkylene . In some embodiments , Ll is 
CH , CH ( OH ) . In some embodiments , L ' is a C - 4 alky 
leneoxy which is further substituted by one OH group . In 
some embodiments , L ' is a propoxy group which is further 
substituted by one OH group . In some embodiments , L ' is 
CH2CH ( OH ) CH20 . In some embodiments , L ' is CEO ) . In some embodiments , L ' is a 4-6 membered heterocycloalkylene . In some embodiments , L ' is a 4-6 
membered heterocycloalkylene comprising one ring het 
eroatom which is nitrogen . In some embodiments , L ' is a 
5 - membered heterocycloalkylene comprising one ring het 
eroatom which is nitrogen . In some embodiments , L ' is : 
R 
R ? & R3 = _OCHZ 
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N 
wherein : 
[ 0215 ] ww indicates the bond between Ll and the 
piperazine group of Formula II ; and 
[ 0216 ] indicates the bond between L ' and Rla . 
[ 0217 ] In some embodiments , Rla is OH . In some embodi 
ments , L ' is a bond and Rla is OH . In some embodiments , 
Rla is a C1-4 alkyl group . In some embodiments , L ' is a bond 
and Rla is a C1-4 alkyl group . In some embodiments , Rla is 
selected from the group consisting of methyl and ethyl . In 
some embodiments , Rla is a C5-10 cycloalkyl group which is 
optionally substituted by one C1-4 alkyl group . In some 
embodiments , Rla is a C5-7 cycloalkyl group which is 
optionally substituted by one C1-4 cycloalkyl group . In some 
embodiments , Rla is a C8-10 cycloalkyl group . In some 
embodiments , R14 is selected from the group consisting of 
cyclopentyl , cyclohexyl , 3 - methylcyclohexyl , cycloheptyl , 
and 
group consisting of phenyl , ( CH2 ) - ( phenyl ) , and ( CH2CH2 )- ( phenyl ) , wherein the phenyl and the phenyl 
group of the — ( CH2 ) - ( phenyl ) and ( CH2CH2 ) - ( phenyl ) 
are each optionally substituted by 1 , 2 , or 3 substituents 
independently selected from the group consisting of halo , 
OH , NO2 , C1-4 alkyl , and C1-4 alkoxy . In some embodi 
ments , the phenyl and the phenyl group of the ( CH2 ) ( phenyl ) and ( CH2CH2 ) - ( phenyl ) are unsubstituted . In 
some embodiments , the phenyl and the phenyl group of the ( CH ) - ( phenyl ) and ( CH2CH2 ) - ( phenyl ) are substituted 
by 1 , 2 , or 3 substituents independently selected from the 
group consisting of halo , OH , NO2 , C - 4 alkyl , and C - 4 
alkoxy . In some embodiments , the phenyl and the phenyl 
group of the ( CH2 ) - ( phenyl ) and ( CH2CH2 ) - ( phenyl ) 
are substituted by 1 , 2 , or 3 substituents independently 
selected from the group consisting of fluoro , chloro , bromo , 
OH , NO2 , methyl , ethyl , 2 - butyl , and methoxy . 
[ 0219 ] In some embodiments , Ria is a 10-13 membered heteroaryl group which is optionally substituted by one halo 
group . In some embodiments , Rla is 10 - membered het 
eroaryl which is substituted by one halo group . In some 
embodiments , Rla is 10 - membered heteroaryl which is sub 
stituted by one halo group and wherein the 10 - membered 
heteroaryl comprises two ring heteroatoms which are nitro 
gen . In some embodiments , Rla is a 13 - membered heteroaryl 
group . In some embodiments , Rla is a 13 - membered het 
eroaryl group comprising two ring heteroatoms which are 
nitrogen and one ring heteroatom which is sulfur . In some 
embodiments , Rla is selected from the group consisting of : 
and 
Br S 
N , and 
N 
In some embodiments , Ria is a 8-10 membered heteroaryl 
group . In some embodiments , Ria is a 8-10 membered 
heteroaryl group comprising two ring heteroatoms which are 
oxygen . In some embodiments , Ria is a 10 - membered het 
eroaryl group comprising two ring heteroatoms which are 
oxygen . In some embodiments , Rla is : 
mm 
[ 0218 ] In some embodiments , Rla is phenyl or ( C1-4 
alkylene ) - ( phenyl ) , wherein the phenyl and the phenyl group 
of the ( C1-4 alkylene ) - ( phenyl ) are each optionally sub 
stituted by 1 , 2 , or 3 substituents independently selected 
from the group consisting of halo , OH , NO2 , C1-4 alkyl , and 
C1-4 alkoxy . In some embodiments , Rla is phenyl or ( C1-4 
alkylene ) - ( phenyl ) , wherein the phenyl and the phenyl group 
of the ( C1-4 alkylene ) - ( phenyl ) are each optionally sub 
stituted by 1 , 2 , or 3 substituents independently selected 
from the group consisting of halo , OH , NO2 , C1-4 alkyl , and 
C1-4 alkoxy . In some embodiments , Rla is selected from the 
[ 0220 ] In some embodiments , R2 is H. In some embodi 
ments , R2 is halo . In some embodiments , R2 is selected from 
the group consisting of F and Cl . In some embodiments , R ? 
is OH . In some embodiments , R2 is C1-4 alkyl . In some 
embodiments , R2 is selected from the group consisting of 
methyl , ethyl , isopropyl , and tert - butyl . In some embodi 
ments , R² is NO2 . In some embodiments , R2 is C -4 alkoxy . 
In some embodiments , R2 is selected from the group con 
sisting of methoxy , ethoxy , and butoxy . 
[ 0221 ] In some embodiments , R ’ is - ( C1-4 alkylene ) - ( 8-10 
membered heteroaryl ) . In some embodiments , R ’ is – ( C1-4 
alkylene ) - ( 8-10 membered heteroaryl ) , wherein the 8-10 
membered heteroaryl group comprises one ring heteroatom 
which is nitrogen . In some embodiments , R² is ( CH2 ) - ( 8 
10 membered heteroaryl ) , wherein the 8-10 membered het 
eroaryl group comprises one ring heteroatom which is 
nitrogen . In some embodiments , R2 is— ( CH2 ) - ( 10 - mem 
bered heteroaryl ) , wherein the 10 - membered heteroaryl 
group comprises one ring heteroatom which is nitrogen . In 
some embodiments , R2 is : 
US 2020/0071735 A1 Mar. 5 , 2020 
25 
and od [ 0222 ] In some embodiments , R3 is H. In some embodi 
ments , R3 is halo . In some embodiments , R3 is selected from 
the group consisting of Cl and Br . In some embodiments , Rº is C1-4 alkoxy or phenoxy . In some embodiments , R3 is 
methoxy or phenoxy . 
[ 0223 ] In some embodiments , R2 and R3 come together , in 
combination with the carbon atoms to which they are 
attached , to form a 5-6 membered heterocycloalkyl or a 
C6-10 aryl . In some embodiments , R2 and R3 come together , 
in combination with the carbon atoms to which they are 
attached , to form a 5-6 membered heterocycloalkyl . In some 
embodiments , R2 and R3 come together , in combination with 
the carbon atoms to which they are attached , to form a 5-6 
membered heterocycloalkyl wherein the 5-6 membered het 
erocycloalkyl comprises two ring atoms which are oxygen . 
In some embodiments , R2 and R3 come together , in combi 
nation with the carbon atoms to which they are attached , to 
form a C6-10 aryl . In some embodiments , R2 and R3 come 
together , in combination with the carbon atoms to which 
they are attached , to form a C , aryl . In some embodiments , 
R2 and R3 come together , in combination with the carbon 
atoms to which they are attached , to form a group selected 
from : 
wherein : 
[ 0224 ] indicates the bond formed by R2 and the 
phenyl group ; and 
[ 0225 ] war indicates the bond formed by R3 and the 
phenyl group . 
[ 0226 ] In some embodiments , R4 is H. In some embodi 
ments , R * is OH . In some embodiments , R * is methoxy . 
[ 0227 ] In some embodiments , RS is H. In some embodi 
ments , R is halo . In some embodiments , Ris selected from 
the group consisting of Cl and Br . In some embodiments , RS 
is C1-4 alkoxy or phenoxy . In some embodiments , RS is 
methoxy or phenoxy . 
[ 0228 ] In some embodiments , Róis H. In some embodi 
ments , R is oxo ( i.e. , = O ) . 
[ 0229 ] In some embodiments , the compound of Formula 
Ila is selected from the group of compounds provided in 
Table 2A . 
TABLE 2A 
( 62 ) 
OH 
N 
( 63 ) 
( 81 ) 
( 100 ) 
N 
HO 
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TABLE 2A - continued 
NO2 ( 29 ) 
NO2 ( 31 ) 
OH 
( 79 ) 
?? 
( 40 ) 
NO2 
NO2 ( 6 ) 
O2N . ( 15 ) 
( 129 ) 
Dwow 
ola 
maor 
( 28 ) 
( 82 ) 
OH 
( 43 ) 
NO2 
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TABLE 2A - continued 
( 121 ) 
( 110 ) 
( 71 ) 
( 96 ) 
( 135 ) 
( 98 ) 
' N 
HO 
( 112 ) 
N 
( 76 ) 
HO 
( 103 ) N 
N. 
( 72 ) 
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TABLE 2A - continued 
( 109 ) 
( 106 ) 
N 
( 9 ) 
NO2 
F 
( 111 ) N 
( 93 ) 
wo 
( 83 ) 
N 
( 97 ) 
HO . 
( 90 ) 
F 
( 91 ) 
F 
N 
( 65 ) 
US 2020/0071735 A1 Mar 5 , 2020 
29 
TABLE 2A - continued 
( 64 ) 
OH 
F ( 78 ) 
( 7 ) 
NO2 
( 41 ) 
NO2 
F. ( 130 ) 
N 
( 42 ) 
NO2 
NO2 ( 32 ) ? 
( 75 ) 
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TABLE 2A - continued 
( 94 ) 
or 
F 
( 13 ) 
NO2 
( 8 ) 
NO2 
( 66 ) 
?? 
CI ma 
dora ( 27 ) NO2 
( 88 ) 
( 4 ) dao NO2 
CI ( 132 ) 
OH 
( 77 ) 
ci 
F 
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TABLE 2A - continued 
( 67 ) 
( 133 ) 
Br 
( 113 ) 
adora F 
( 16 ) 
NO2 
N 
( 26 ) 
N 
O2N 
HO . ( 34 ) 
N 
ON Br 
( 131 ) 
U 
HO . ( 123 ) 
and 
Br 
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TABLE 2A - continued 
( 95 ) hora 
TABLE 3 - continued or a pharmaceutically acceptable salt thereof . In some 
embodiments , the pharmaceutically acceptable salt is a 
hydrochloride salt . Substituents of Formula III 
[ 0230 ] The present application further provides a com 
pound of Formula III : R2 = N 2HC1 
III 
R1 = 
R2 
R impone 
HCI 
R = 
moto HN 
??? 
R = 
or a pharmaceutically acceptable salt thereof , wherein R1 
and R2 of Formula III are as defined herein . 
[ 0231 ] In some embodiments , each rl and R ?, unless 
specified otherwise in Table 3 , is selected from the group 
consisting of H , OH , SH , CN , NO2 , halo , oxo , C1-6 alkyl , 
C2-6 alkenyl , C2-6 alkynyl , C1-6 haloalkyl , C1-6 cyanoalkyl , 
C1-6 hydroxyalkyl , C1-6 alkoxy , ( C1-6 alkyl ) - ( C1-6 alkoxy ) , 
-C1-6 alkoxy ) - ( C - 6 alkoxy ) , C1.6 haloalkoxy , C3-10 
cycloalkyl , C6-10 aryl , 5-10 membered heteroaryl , 4-10 
membered heterocycloalkyl , amino , C - alkylamino , 
di ( C1-6 alkyl ) amino , carbamyl , C1-6 alkylcarbamyl , di ( C1-6 
alkyl ) carbamyl , carbamoyl , C- , alkylcarbamoyl , di ( C - 6 
alkyl ) carbamoyl , C1-6 alkylcarbonyl , C1-6 alkoxycarbonyl , 
C1-6 alkylcarbonylamino , C1-6 alkylsulfonylamino , amino 
sulfonyl , C1-6 alkylaminosulfonyl , di ( C1-6 alkyl ) aminosul fonyl , aminosulfonylamino , Cl . alkylaminosulfonylamino , 
di ( C1-6 alkyl ) aminosulfonylamino , aminocarbonylamino , 
C - alkylaminocarbonylamino , and di ( C1 - alkyl ) aminocar 
bonylamino . In some embodiments , each R and R2 unless 
specified otherwise in Table 3 , is H. In some embodiments , 
at least one of R1 and R2 is not H. 
O 
R2 = ? mapun 
TABLE 3 
R1 = 
Substituents of Formula III 
R ! 
R2 
R ? ont 
reix R2 = R ! 
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TABLE 3 - continued 
Substituents of Formula III 
R = 
NH HCI 
ro 
R1 = ti HCI 1 HN 
[ 0235 ] L is selected from the group consisting of a bond 
and 5-6 membered heterocycloalkyl ; and 
[ 0236 ] R24 is selected from the group consisting of H , C1-4 
hydroxyalkyl , -SO ( C1-4 alkyl ) . 
[ 0237 ] In some embodiments , L ' is a bond . In some 
embodiments , L ' is selected from the group consisting of 
NH and N ( C1-4 alkyl ) . In some embodiments , L ' is selected 
from the group consisting of NH and N ( CH3 ) . In some 
embodiments , L ' is C2-4 alkynyl . In some embodiments , L ' is —C = CCH_— . In some embodiments , L ' is NHC ( O ) ( C1-4 thioalkyl ) . In some embodiments , L ' is L ' is NHC 
FO ) CH S— . In some embodiments , L ' is C1-6 alkylene 
oxy which is further substituted by one OH group . In some 
embodiments , L ' is CH CH OCH CH ( OH ) CH2 . In some 
embodiments , L ' is a 5-6 membered heterocycloalkyl group . 
In some embodiments , L ' is a 5-6 membered heterocy 
cloalkyl group wherein the 5-6 membered heterocycloalkyl 
group comprises two ring heteroatoms which are nitrogen . 
In some embodiments , L ' is piperazinyl . In some embodi 
ments , L ' is selected from the group consisting of NHC 
FO ) C1-4 alkylene and ( C1-4 alkylene ) -NHC ( = O ) ( C1-4 
alkylene ) - . In some embodiments , Ll is selected from the 
group consisting of - NHC ( O ) CH2- and —CH NHC 
FO ) CH2 — 
[ 0238 ] In some embodiments , Rais H. In some embodi 
ments , L ' is a bond and Ria is H. In some embodiments , Ria 
is selected from the group consisting of C - 4 alkyl , C2-4 
alkenyl , and C1-4 cyanoalkyl , wherein the C1-4 alkyl and C2-4 
alkenyl are each optionally substituted by one substituent 
selected from the group consisting of phenyl and hydroxy 
phenyl . In some embodiments , Rla is selected from the 
group consisting of CH2CH2CN , 
HO 
R1 = 
HN 
S NH2 / 
N 
[ 0232 ] The present application further provides a com 
pound of Formula IIIa : 
IIIa 
12 - R2 
OH , and 
R 
or a pharmaceutically acceptable salt thereof , wherein : 
[ 0233 ] L ' is selected from the group consisting of a bond , 
NH , N ( C1-4 alkyl ) , C2-4 alkynyl , NHC ( = O ) ( C1-4 thioalkyl ) , C1-6 alkyleneoxy , 5-6 membered heterocycloalkyl , NHC ( 0 ) C - 4 alkylene , and ( C1-4 alkylene ) -NHC ( O ) ( C - 4 
alkylene ) - , wherein the C1-6 alkyleneoxy is further option 
ally substituted by one OH group ; 
[ 0234 ] Rla is selected from the group consisting of H , C1-4 
alkyl , C2-4 alkenyl , C1-4 cyanoalkylene , 5-6 membered het 
erocycloalkyl , 5-6 membered heteroaryl , NH ( C1-4 alkyl ) , 
and NH ( C24 alkenyl ) , wherein the C - 4 alkyl and C24 
alkenyl are each optionally substituted by one substituent 
selected from the group consisting of phenyl and hydroxy 
phenyl , and wherein the 5-6 membered heterocycloalkyl and 
5-6 membered heteroaryl are each optionally substituted by 
1 or 2 substituents independently selected from the group 
consisting of C1-4 alkyl , NH , and di - halo substituted phenyl ; 
[ 0239 ] In some embodiments , Rla is selected from the 
group consisting of 5-6 membered heterocycloalkyl and 5-6 
membered heteroaryl , wherein the 5-6 membered heterocy 
cloalkyl and 5-6 membered heteroaryl are each optionally 
substituted by 1 or 2 substituents independently selected 
from the group consisting of C1-4 alkyl , NH , and di - halo 
substituted phenyl . In some embodiments , Rla is selected from the group consisting of 6 - membered heterocycloalkyl 
and 5 - membered heteroaryl , wherein the 6 - membered het 
erocycloalkyl and 5 - membered heteroaryl are each option 
ally substituted by 1 or 2 substituents independently selected 
from the group consisting of methyl , ethyl , NH , and di - halo 
substituted phenyl . In some embodiments , Rla is selected 
from the group consisting of : 
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TABLE 3A - continued 
and 
( 149 ) + disor NH2 / Cl . CI ( 138 ) 
OH 
[ 0240 ] In some embodiments , Rla is selected from the 
group consisting of NH ( C1-4 alkyl ) and NH ( C2-4 alkenyl ) . In 
some embodiments , Rla is NH ( CH ( CH3 ) 2 ) . In some 
embodiments , Rla is NH ( CH2CH = CH2 ) . [ 0241 ] In some embodiments , L2 is a bond . In some 
embodiments , L ’ is a 5-6 membered heterocycloalkyl group . 
In some embodiments , L2 is a 5-6 membered heterocy 
cloalkyl group , wherein the 5-6 membered heterocycloalkyl 
group comprises two ring heteroatoms which are nitrogen . 
In some embodiments , L² is a 6 - membered heterocycloalkyl 
group , wherein the 6 - membered heterocycloalkyl group 
comprises two ring heteroatoms which are nitrogen . In some 
embodiments , L² is piperazinyl . 
[ 0242 ] In some embodiments , R2a is H. In some embodi 
ments , L2 is a bond and R24 is H. In some embodiments , R2a 
is SO2 ( C1-4 alkyl ) . In some embodiments , R24 is SO CHz . In 
some embodiments , R2a is C1-4 hydroxyalkyl . In some 
embodiments , R24 is CH CH OH . 
[ 0243 ] In some embodiments , the compound of Formula 
IIIa is selected from the group of compounds provided in 
Table 3A . 
( 145 ) OH 
OH ( 137 ) 
TABLE 3A 
( 144 ) 
( 139 ) 
// 
( 136 ) 
( 140 ) 
N 
N 
( 143 ) 
( 146 ) 
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TABLE 3A - continued TABLE 4 - continued 
R2 ( 142 ) 
R3 NO2 
HN R1 " R4 
RS 
Cmpd 
# Substituent Groups ( 147 ) 
2 R = 
Oro alot 3 R1 - N ( 141 ) 
4 R1 = 
[ 0244 ] or a pharmaceutically acceptable salt thereof . In 
some embodiments , the pharmaceutically acceptable salt is 
a hydrochloride salt . 
[ 0245 ] In some embodiments , the compound is selected 
from the group provided in Table 4 , or a pharmaceutically 
acceptable salt thereof . Unless specified otherwise , each R 
group of Table 4 is H. 
5 Ri = 
Xox TABLE 4 
R } NO2 6 R1 = 
R ? R4 
RS 
7 R = 
Cmpd 
# Substituent Groups 
R1 = 
8 your R = 
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TABLE 4 - continued TABLE 4 - continued 
R2 
R3 NO2 R3 NO2 
RI R4 R1 R4 
RS RS 
Cmpd 
# Substituent Groups 
Cmpd 
# Substituent Groups 
9 R = 17 R2 = CH3 
R3 = F. 
F N 
F co 
alt 11 R1 = 18 Ri = CH3 R3 = 
12 R = 
N. 
19 RI = 
13 R1 = 
20 R1 = 
14 R1 = 
ot NH 
15 R = 
21 R = 
16 R1 = 
22 R3 = Ex Ort 
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TABLE 4 - continued TABLE 4 - continued 
R2 R2 
NO2 R } NO2 
R1 R4 R ! R4 
RS R5 
Cmpd 
# Substituent Groups 
Cmpd 
# Substituent Groups 
29 23 R1 = R & R3 = 
F 
30 R = 
N 
S 
wherein : 
refers to the bond connecting Ri to Formula I ; and 
w refers to the bond connecting R3 to Formula I 
NE 
24 R3 = 
31 Ri = 
N 
N 
R4 = OMe OH 
25 R = 32 R. 
?? 
33 Ri = 
26 RI = infun 
R2 
27 R1 = 
tao 
cox 
" Xore 
34 R = 
28 Br xox 
tyy 35 R2 = 
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TABLE 4 - continued TABLE 4 - continued 
R2 R2 
R ] NO2 R3 NO2 ? R ! R4 R1 " R4 RS RS
Cmpd 
# Substituent Groups 
Cmpd 
# Substituent Groups 
43 36 R = R1 = tang 
Hora 37 R1 = 44 R OSO R5 = CI 
38 R1 = t 45 R2 = # C1 
CI 
R5 = 39 R2 = ' N 
40 Ri = 
46 R3 = yax 
41 R. R4 = 007 
47 R2 = CH3 
42 R = 
R3 = N con orst Br 
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TABLE 4 - continued TABLE 4 - continued 
R2 
R } NO2 R3 NO2 
R ! R4 
R ! R4 
R5 
RS 
Cmpd 
# Substituent Groups Cmpd 
# Substituent Groups 53 R1 = 
mm 
48 RS 
NH 
54 R2 = CH3 
RS = 
49 
NH 
IZ 
RS 
*** yax 
gay 
55 R2 = CH3 
R3 = 
mm 
50 R3 = 
NH Why 
R4 = -SCH2CH3 
56 R = F 
51 F. R3 = 
-OCH3 
R4 = 
orix 57 R2 = 
52 R3 = = CH3 
R4 ont ha R = C1 
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TABLE 4 - continued TABLE 5 
R3 R7 R2 NO2 
RO 
R ? R4 R5 
RS R4 
Cmpd 
# Substituent Groups N 
R 
58 R1 = 
Cmpd # Substituent Groups 
+ 4 R1 = 
R2 = NO2 
6 
59 7 F R1 = 
R ? = benzyl 
R3 = NO2 
R ' = phenyl 
R2 = NO2 
R ! = p - nitrophenyl 
R2 = _OCH2CH3 
F 8 infun 
9 R = F F 
F 
RS -OCH3 
F 
R2 = NO2 
13 R1 = 
60 R2 = 
NH 
R2 = NO2 
15 R ' = p - nitrophenyl 
R = _OCH2CH2CH2CH3 
16 R1 = 
61 R5 = 
ento 
.cl 
ZT 
R2 = NO2 
24 R1 = Ci 
ON 
R2 & R3 
-OCH3 
[ 0246 ] In some embodiments , the compound is selected 
from the group provided in Table 5 , or a pharmaceutically 
acceptable salt thereof . Unless specified otherwise , each R 
group of Table 5 is H. 
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TABLE 5 - continued TABLE 5 - continued 
R3 
R7 R2 R ? R2 
R6 R6 
R5 R5 
R4 R4 
N 
R ? R1 
Cmpd # Substituent Groups Cmpd # Substituent Groups 
41 27 Ri = R1 = 
O2N 
R2 = NO2 R3 & R4 = OCH3 
42 
28 R = 
R ? = cyclopentyl 
R ? = NO2 
R ' = cycloheptyl 
R2 = NO2 
43 
62 O2N R1 = 
R2 & R4 = -OCH ; ? 29 R1 = 
R2 = OH 
O2N 
63 R7 = F Ri = 
31 RIN NO2 
64 R1 = OH os 32 R = 
65 R = 
R2 = NO2 
R6 = 
34 R. R2 = OCH3 
R3 & R4 = CH3 
O2N 66 R1 
RS = Br C R7 = OH 40 R ? = sec - butyl 
R ? = NO2 R2 = OH 
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TABLE 5 - continued TABLE 5 - continued 
R3 R3 
R7 R2 R7 R2 
R6 R6 R5 RS 
R4 R4 
-Z 
- 
R R ? 
Cmpd # Substituent Groups 
Cmpd # Substituent Groups 
67 R1 = C1 
75 R 
R ? & R3 = 
R2 = C1 t 76 R : 
wherein : 
refers to the bond connecting R² to Formula II ; and 
w refers to the bond connecting R3 to Formula II R2 = OH 
68 R1 = 
77 R1 
R2 = CI R2 = F 
69 R1 = 
78 R1 
R2 = F 
70 79 
71 
R = CH3 
R2 = isopropyl 
R1 and R2 = ethyl 
R ' = trans - cinnamyl 
R2 = OCH3 
81 
72 
R ? = benzyl 
R2 = OH 
R ? = benzyl 
R ?, R4 , and R $ = OCHZ 
R ' = phenyl 
R ? = OH 
82 
74 R1 = 
83 R1 = CH3 
RS 
R2 = NO3 
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TABLE 5 - continued TABLE 5 - continued 
R ? R2 R ? R2 
R6 R6 
R5 R5 
R4 R4 
' N N 
- 
R R1 
Cmpd # Substituent Groups Cmpd # Substituent Groups 
84 R = 95 R1 = 
R2 = ethyl 
R2 = -OCH2CH3 
86 R ? = phenyl 
R2 = Br 96 R = 
88 Ri = 
R2 = F 
R2 = -OCH2CH3 97 
90 R = 98 
R == CH2CH2OH 
R ? = isopropyl 
R1 CH2CH2OH 
R2 = ethyl 
R ' = benzyl 
R3 & R = OCH3 
R ' = -CH2CH2OH 
R ? = CH3 
99 
100 
F. 
R2 = CH3 R1 = 
91 R1 = 
R2 , R3 , and R5 -OCH3 
R2 = F 
R6 = 
93 R ! = 103 Ri = CH3 
R2 & R3 = og 
o 
R2 = CH3 
94 Ri = wherein : 
refers to the bond connecting R2 to Formula II ; and 
w refers to the bond connecting R3 to Formula II 
F 104 R1 = ethyl 
R2 = N ( ethyl ) 2 R2 = —OCH2CH3 
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TABLE 5 - continued TABLE 5 - continued 
R7 R2 R ? R2 
R6 R6 R5 R5 
R4 R4 
' N N 
- 
R ] R ! 
Cmpd # Substituent Groups 
Cmpd # Substituent Groups 
106 Ri = 
113 R1 = 
F 
107 R1 = benzyl 
R5 - ci 
R7 - OH 
R4 & R = —OCHZ 
120 R1 = 109 R1 = to 
ot 110 R1 = R6 = 0 R7 = OCH3 
111 Ri = 121 R ' = cyclohexyl 
123 RI 
112 Ri = 
RS = Br 
R7 = OH 
124 R1 = 
R2 & R3 = 
R7 = NO3 
129 
wherein : 
R1 ethyl 
R2 = tert - butyl 
R = 0 refers to the bond connecting R² to Formula II ; and 
in refers to the bond connecting R3 to Formula II 
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TABLE 5 - continued TABLE 6 
R7 R² ?? R2 R6 R ? 
R5 
Cmpd # Substituent Groups 
R4 
136 
137 
138 
139 
140 
R ! 
R ? 
R ? 
R ? 
R2 
R ! 
141 R1 = 
Cmpd # Substituent Groups impone 
130 R1 = F. 
HCI 
142 Ri = mohon HN i R2 = HCI 
143 R6 = 0 R = 
131 R = 
o 
144 R2 = 
R2 = -OCH3 
132 R = CI tot CI 
145 Ri = 
2HCI 
OH 
OH 
133 R. 2HCI 
146 Ri = 
Br 
' N 
HCI HCI N 
147 R 
134 R1 - 
135 R1 = 
R ? & R² = OCH3 
NH ??? ng N [ 0247 ] In some embodiments , the compound is selected from the group provided in Table 6 , or a pharmaceutically 
acceptable salt thereof . Unless specified otherwise , each R 
group of Table 6 is H. 
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TABLE 6 - continued 
? * R2 R ! 
Cmpd # Substituent Groups 
148 R1 = 
HCI 
[ 0267 ] 1 - benzyl - 4- ( bicyclo [ 2.2.1 ] heptan - 2 - yl ) piperazine . 
[ 0268 ] In some embodiments , the compound is selected 
from the group consisting of : [ 0269 ] ( 2- ( 3,4 - dimethoxyphenyl ) -N - methyl - N- ( 4 - ni 
trobenzyl ) ethan - 1 - amine ) ; [ 0270 ] ( 4- ( 4- ( 2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ) ; and 
[ 0271 ] ( 3- ( adamantan - 1 - yl ( methyl ) amino ) propanenitrile ; 
or a pharmaceutically acceptable salt thereof . 
[ 0272 ] In some embodiments , the compound is selected 
from the group consisting of : 
[ 0273 ] ( 2- ( 3,4 - dimethoxyphenyl ) -N - methyl - N- ( 4 - ni 
trobenzyl ) ethan - 1 - amine ) ; [ 0274 ] ( 4- ( 4- ( 2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ) ; and [ 0275 ] ( 3- ( adamantan - 1 - ylmethyl ) amino ) propanenitrile ; 
or a pharmaceutically acceptable salt thereof . 
[ 0276 ] In some embodiments , the compound is selected 
from the group consisting of : 
[ 0277 ] ( 2- ( 3,4 - dimethoxyphenyl ) -N - methyl - N- ( 4 - ni 
trobenzyl ) ethan - 1 - amine ) ; [ 0278 ] ( 4 - ( [ 4- ( 2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ) ; and 
[ 0279 ] ( 3- ( adamantan - 1 - yl ( methyl ) amino ) propanenitrile 
hydrochloride ) . [ 0280 ] The phrase " pharmaceutically acceptable " is 
employed herein to refer to those compounds or salts which 
are suitable for use in contact with cells ( e.g. , eukaryotic 
cells or cyanobacteria ) without excessive toxicity or other 
problem or complication ( i.e. , the contacting does not affect 
the viability of the cell ) . 
?? . 
149 R1 = 
HN 
NH2 / 
CI 
CI 
Methods of Use 
[ 0248 ] In some embodiments , the compound is selected from the group of compounds provided in Table 1A , Table 
1B , Table 1C , Table 2A , Table 3A , Table 4 , Table 5 , and 
Table 6 , or a pharmaceutically acceptable salt thereof . [ 0249 ] In some embodiments , the compound is selected from the group consisting of : [ 0250 ] 2- ( 3,4 - dimethoxyphenyl ) -N - methyl - N- ( 4 - ni 
trobenzyl ) ethan - 1 - amine ; [ 0251 ] N - methyl - N- ( 4 - nitrobenzyl ) cyclohexanamine ; [ 0252 ] 3- ( adamantan - 1 - yl ( methyl ) amino propanenitrile ; [ 0253 ] 1- ( adamantan - 2 - yl ) -4- ( methyl sulfonyl ) piperazine ; [ 0254 ] 4- ( 4- ( 2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ; 
[ 0255 ] ( 4 - benzylpiperazin - 1 - yl ) ( 2,3 - dihydrobenzo [ b ] 1,4 ] 
dioxin - 2 - yl ) methanone ; [ 0256 ] 1 - cinnamyl - 4- ( 4 - methoxybenzyl ) piperazine ; [ 0257 ] 1- ( 4 - fluorobenzyl ) -4 - o - tolyl ) piperazine ; and [ 0258 ] 1 - benzyl - 4- ( bicyclo [ 2.2.1 ] heptan - 2 - yl ) piperazine ; 
or a pharmaceutically acceptable salt thereof . 
[ 0259 ] In some embodiments , the compound is selected 
from the group consisting of : 
[ 0260 ] 2- ( 3,4 - dimethoxyphenyl ) -N - methyl - N- ( 4 - ni 
trobenzyl ) ethan - 1 - amine ; N - methyl - N- ( 4 - nitrobenzyl ) cyclo 
hexanamine ; [ 0261 ] 3- ( adamantan - 1 - yl ( methyl ) amino propanenitrile 
hydrochloride ; 
[ 0262 ] 1- ( adamantan - 2 - yl ) -4- ( methyl sulfonyl ) piperazine ; 
[ 0263 ] 4 - ( ( 4- ( 2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ; 
[ 0264 ] ( 4 - benzylpiperazin - 1 - yl ) ( 2,3 - dihydrobenzo [ b ] 1,4 ] 
dioxin - 2 - yl ) methanone hydrochloride ; [ 0265 ] 1 - cinnamyl - 4- ( 4 - methoxybenzyl ) piperazine ; 
[ 0266 ] 1- ( 4 - fluorobenzyl ) -4- ( 0 - tolyl ) piperazine ; and 
[ 0281 ] The present application further provides a method 
of increasing lipid accumulation in a cell , comprising con 
tacting the cell with an effective amount of a compound 
provided herein ( e.g. a compound of any one of Formulae I , 
Ia , Ib , Ic , II , IIa , III , and Illa , or a pharmaceutically accept 
able salt thereof ) . In some embodiments , the compound is a 
compound of Formula Ia , or a pharmaceutically acceptable 
salt thereof , or a compound of Formula Ib , or a pharmaceu 
tically acceptable salt thereof , or a compound of Formula Ic , 
or a pharmaceutically acceptable salt thereof , or a compound 
of Formula Ila , or a pharmaceutically acceptable salt 
thereof , or a compound of Formula IIIa , or a pharmaceuti 
cally acceptable salt thereof . In some embodiments , the 
compound is a compound of Formula I , or a pharmaceuti 
cally acceptable salt thereof . In some embodiments , the 
compound is a compound of Formula II , or a pharmaceuti 
cally acceptable salt thereof . In some embodiments , the 
compound is a compound of Formula III , or a pharmaceu 
tically acceptable salt thereof . In some embodiments , the 
compound is selected from the group of compounds pro 
vided in Table 1A , Table 1B , Table 1C , Table 2A , Table 3A , 
Table 4 , Table 5 , and Table 6 , or a pharmaceutically accept 
able salt thereof . 
[ 0282 ] In some embodiments , the compound is selected 
from the group consisting of : 
[ 0283 ] 2- ( 3,4 - dimethoxyphenyl ) -N - methyl - N- ( 4 - ni 
trobenzyl ) ethan - 1 - amine ; [ 0284 ] N - methyl - N- ( 4 - nitrobenzyl cyclohexanamine ; 
[ 0285 ] 3- ( adamantan - 1 - yl ( methyl ) amino propanenitrile ; 
[ 0286 ] 1- ( adamantan - 2 - yl ) -4 - methyl sulfonyl ) piperazine ; 
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[ 0287 ] 4- ( 4- ( 2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ; 
[ 0288 ] ( 4 - benzylpiperazin - 1 - yl ) ( 2,3 - dihydrobenzo [ b ] 1,4 ] 
dioxin - 2 - yl ) methanone ; 
[ 0289 ] 1 - cinnamyl - 4- ( 4 - methoxybenzyl ) piperazine ; 
[ 0290 ] 1- ( 4 - fluorobenzyl ) -4 - o - tolyl ) piperazine ; and 
[ 0291 ] 1 - benzyl - 4- ( bicyclo [ 2.2.1 ] heptan - 2 - yl ) piperazine ; 
or a pharmaceutically acceptable salt thereof . 
[ 0292 ] In some embodiments , the compound is selected 
from the group consisting of : 
[ 0293 ] 2- ( 3,4 - dimethoxyphenyl ) -N - methyl - N- ( 4 - ni 
trobenzyl ) ethan - 1 - amine ; 
[ 0294 ] N - methyl - N- ( 4 - nitrobenzyl ) cyclohexanamine ; 
[ 0295 ] 3- ( adamantan - 1 - yl ( methyl ) amino ) propanenitrile 
hydrochloride ; 
[ 0296 ] 1- ( adamantan - 2 - yl ) -4- ( methyl sulfonyl ) piperazine ; [ 0297 ] 4- ( 4- ( 2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ; 
[ 0298 ] ( 4 - benzylpiperazin - 1 - yl ) ( 2,3 - dihydrobenzo [ b ] 1,4 ] 
dioxin - 2 - yl ) methanone hydrochloride ; 
[ 0299 ) 1 - cinnamyl - 4- ( 4 - methoxybenzyl ) piperazine ; 
[ 0300 ) 1- ( 4 - fluorobenzyl ) -4-0 - tolyl ) piperazine ; and 
[ 0301 ] 1 - benzyl - 4- ( bicyclo [ 2.2.1 ] heptan - 2 - yl ) piperazine . 
[ 0302 ] In some embodiments , the compound is selected from the group consisting of : 
[ 0303 ] ( 2- ( 3,4 - dimethoxyphenyl ) -N - methyl - N- ( 4 - ni 
trobenzyl ) ethan - 1 - amine ) ; 
[ 0304 ] ( 4 - ( [ 4- ( 2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ) ; and 
[ 0305 ] ( 3- ( adamantan - 1 - yl ( methyl ) amino ) propanenitrile ; 
or a pharmaceutically acceptable salt thereof . 
[ 0306 ] In some embodiments , the compound is selected from the group consisting of : 
[ 0307 ] ( 2- ( 3,4 - dimethoxyphenyl ) -N - methyl - N- ( 4 - ni 
trobenzyl ) ethan - 1 - amine ) ; 
[ 0308 ] ( 4- ( 4- ( 2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ) ; and 
[ 0309 ] ( 3- ( adamantan - 1 - yl ( methyl ) amino propanenitrile 
hydrochloride ) . 
[ 0310 ] In some embodiments , the cell is a eukaryotic cell 
or a cyanobacteria . In some embodiments , the cell is a 
eukaryotic cell . In some embodiments , the cell is a cyano 
bacteria . In some embodiments , the cell is selected from the group consisting of an algal cell , a drosophila cell , a yeast 
cell , or a fungus cell . 
[ 0311 ] Example algal cells include , but are not limited to , 
Chlamydomonas reinhardtii , Chlorella sorokiniana , Tetra 
chlorella alterans , C. protothecoides , C. vulgaris , Nanno 
chloropsis sp . , P. tricornutum , N. salina , Nannochloris sp . , 
N. oculata , Clostridium acetobutylicum , Botryococcus 
braunii , Dunaliella tertiolecta , Gracilaria , Chlorella sp . , 
Pleurochrysis carterae , Sargassum , Ankistrodesmus , 
[ 0312 ] Example yeast cells include , but are not limited to , 
Yarrowia hpolytica , Saccharomyces cerevisiae , Brettanomy 
ces bruxellensis , Candida stellata , Schizosaccharomyces pombe , Torulaspora delbrueckii , and Zygosaccharomyces 
bailii . 
[ 0313 ] Example fungus cells include , but are not limited 
to , Gliocladium roseum , Cunninghamella japonica , and 
Tricoderma reesei . 
[ 0314 ] In some embodiments , the cell is an algal cell . In 
some embodiments , the cell is selected from the group 
consisting of : 
[ 0315 ) Chlamydomonas reinhardtii ; 
[ 0316 ] Chlorella sorokiniana ; 
[ 0317 ] Tetrachlorella alterans ; [ 0318 ] C. protothecoides ; 
[ 0319 ] C. vulgaris ; and [ 0320 ] Nannochloropsis sp . [ 0321 ] In some embodiments , the cell is an algal cell . In 
some embodiments , the cell is selected from the group 
consisting of : 
[ 0322 ] Chlamydomonas reinhardtii CC 125 ; 
[ 0323 ] Chlorella sorokiniana UTEX 1230 ; 
[ 0324 ] Tetrachlorella alterans UTEX 2453 ; ( 0325 ] C. protothecoides ; 
[ 0326 ] C. vulgaris UTEX 395 ; and [ 0327 ] Nannochloropsis sp . 
[ 0328 ] In some embodiments , the increasing lipid accu 
mulation comprises increasing fatty acid accumulation . In 
some embodiments , the increasing fatty acid accumulation 
comprises increasing C10-30 fatty acid accumulation . In 
some embodiments , the increasing fatty acid accumulation 
comprises increasing C10-20 fatty acid accumulation . In 
some embodiments , the increasing fatty acid accumulation 
comprises increasing C16-18 fatty acid accumulation . In 
some embodiments , increasing lipid accumulation com 
prises increasing polyunsaturated fatty acid accumulation . In 
some embodiments , the increasing polyunsaturated fatty 
acid accumulation comprises increasing C10-30 polyunsatu 
rated fatty acid accumulation . In some embodiments , the increasing polyunsaturated fatty acid accumulation com 
prises increasing C10-20 polyunsaturated fatty acid accumu 
lation . In some embodiments , the increasing polyunsatu 
rated fatty acid accumulation comprises increasing C16-18 
polyunsaturated fatty acid accumulation . 
[ 0329 ] In some embodiments , the increasing lipid accu 
mulation comprises increasing triacylglycerol accumulation . 
In some embodiments , the increasing triacylglycerol accu 
mulation comprises increasing C30-60 triacylglycerol accu 
mulation . In some embodiments , the increasing triacylglyc 
erol accumulation comprises increasing 
triacylglycerol accumulation . In some embodiments , the triacylglycerol comprises fatty acids of C10-20 in chain 
length . In some embodiments , the triacylglycerol comprises 
fatty acids of C15-20 in chain length . In some embodiments , 
the triacylglycerol comprises fatty acids of 16 carbons in 
chain length . In some embodiments , the triacylglycerol 
comprises fatty acids of 18 carbons in chain length . In some 
embodiments , the triacylglycerol comprises fatty acids of 16 
carbons and 18 carbons in chain length . [ 0330 ] In some embodiments , the increasing lipid accu 
mulation comprises increasing fatty acid accumulation and 
increasing triacylglycerol accumulation . In some embodi 
ments , the increasing lipid accumulation comprises increas ing polyunsaturated fatty acid accumulation and increasing 
triacylglycerol accumulation . 
[ 0331 ] In some embodiments , the method further com prises increasing carbohydrate accumulation in the cell . For 
example , the carbohydrate accumulation may be increased 
by about 1.1 to about 5 fold , from about 1.25 to about 5 fold , 
from about 1.5 to about 5 fold , from about 1.75 to about 5 
fold , from about 2 to about 5 fold , from about 2.25 to about 
5 fold , from about 2.5 to about 5 fold , from about 2.75 to 
C40-60 
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about 5 fold , from about 3 to about 5 fold , from about 3.25 
to about 5 fold , from about 3.5 to about 5 fold , from about 
3.75 to about 5 fold , from about 4 to about 5 fold , from about 
4.25 to about 5 fold , from about 4.5 to about 5 fold , or from 
about 4.75 to about 5 fold . In some embodiments , the 
method further comprises increasing carbohydrate accumu 
lation in the cell by about 1.25 to about 3.25 fold . In some 
embodiments , the method further comprises increasing car bohydrate accumulation in the cell by about 1.25 fold . In 
some embodiments , the method further comprises increas 
ing carbohydrate accumulation in the cell by about 2 fold . In 
some embodiments , the method further comprises increas 
ing carbohydrate accumulation in the cell by about 3.2 fold . 
[ 0332 ] In some embodiments , the method further com 
prises increasing carbohydrate production in the cell . For 
example , the carbohydrate production may be increased by 
about 1.1 to about 5 fold , from about 1.25 to about 5 fold , 
from about 1.5 to about 5 fold , from about 1.75 to about 5 
fold , from about 2 to about 5 fold , from about 2.25 to about 
5 fold , from about 2.5 to about 5 fold , from about 2.75 to 
about 5 fold , from about 3 to about 5 fold , from about 3.25 
to about 5 fold , from about 3.5 to about 5 fold , from about 
3.75 to about 5 fold , from about 4 to about 5 fold , from about 
4.25 to about 5 fold , from about 4.5 to about 5 fold , or from 
about 4.75 to about 5 fold . In some embodiments , the 
method further comprises increasing carbohydrate produc 
tion in the cell by about 1.25 to about 3.25 fold . In some 
embodiments , the method further comprises increasing car bohydrate production in the cell by about 1.25 fold . In some 
embodiments , the method further comprises increasing car 
bohydrate production in the cell by about 2 fold . In some 
embodiments , the method further comprises increasing car 
bohydrate production in the cell by about 3.2 fold . 
[ 0333 ] In some embodiments , the method further com prises increasing carbohydrate accumulation in the cell and 
increasing carbohydrate production in the cell . 
[ 0334 ] In some embodiments , the lipid accumulation is 
increased by greater than about 1.5 fold as compared to a cell 
that has not been contacted by the compound , for example , 
greater than about 1.5 fold , greater than about 2 fold , greater 
than about 2.5 fold , greater than about 3 fold , greater than 
about 3.5 fold , greater than about 4 fold , greater than about 
4.5 fold , or greater than about 5 fold as compared to a cell 
that has not been contacted by the compound . In some 
embodiments , the lipid accumulation is increased by greater 
than about 2 - fold as compared to a cell that has not been 
contacted by the compound . In some embodiments , the lipid 
accumulation is increased by greater than about 2.5 - fold as 
compared to a cell that has not been contacted by the 
compound . 
[ 0335 ] In some embodiments , the contacting the cell with 
the compound does not reduce the rate of cellular growth 
compared to a cell that has not been contacted by the 
compound . 
[ 0336 ] In some embodiments , contacting the cell with the 
compound does not reduce the rate of photosynthesis of the 
cell compared to a cell that has not been contacted by the 
compound . For example , the rate of photosynthesis of the 
cell is not reduced if the amount of Chlorophyll A and B , 
carotenoid , and RuBisCO ( Ribulose - 1,5 - bisphosphate car boxylase / oxygenase ) in a cell contacted by a compound 
provided herein are about equivalent to a cell that has not 
been contacted by the compound . In some embodiments , the 
amount of Chlorophyll A and B , carotenoid , and RuBisCO 
( Ribulose - 1,5 - bisphosphate carboxylase / oxygenase ) in a 
cell that has been contacted by a compound provided herein 
are about equivalent to a cell that has not been contacted by 
the compound . 
[ 0337 ] In some embodiments , the contacting does not 
adversely affect the viability of the cell . For example , the 
viability of the cell may include , but is not limited to , 
cellular growth , total cellular protein levels , the level of 
Chlorophyll A in a cell , the level of Chlorophyll B in a cell , 
the level of carotenoid in a cell , the level of RuBisCO ( Ribulose - 1,5 - bisphosphate carboxylaseloxygenase ) in a 
cell , the level of carbohydrates in a cell , the level of nitrogen 
in a cell , the level of sulfur in a cell , and the level of metal 
content in a cell , or any combination thereof . 
[ 0338 ] In some embodiments , the lipid accumulation is 
increased without exposing the cell to environmental stress . 
As used herein , the term “ environmental stress ” refers to a 
stress upon the cell that may result in a decrease or loss of 
cell viability . In some embodiments , the environmental 
stress comprises nutrient deprivation . In some embodiments , 
the environmental stress comprises depriving the cell of 
nitrogen , depriving the cell of sulfur , depriving the cell of 
metal , or any combination thereof . 
[ 0339 ] The present application further provides a method 
of increasing lipid production in a cell , comprising contact 
ing the cell with an effective amount of a compound pro 
vided herein ( e.g. a compound of any one of Formulae I , la , 
Ib , Ic , II , IIa , III , and Illa , or a pharmaceutically acceptable 
salt thereof ) . In some embodiments , the compound is a 
compound of Formula Ia , or a pharmaceutically acceptable 
salt thereof , or a compound of Formula lb , or a pharmaceu 
tically acceptable salt thereof , or a compound of Formula Ic , 
or a pharmaceutically acceptable salt thereof , or a compound 
of Formula Ila , or a pharmaceutically acceptable salt 
thereof , or a compound of Formula IIIa , or a pharmaceuti 
cally acceptable salt thereof . In some embodiments , the 
compound is a compound of Formula I , or a pharmaceuti 
cally acceptable salt thereof . In some embodiments , the 
compound is a compound of Formula II , or a pharmaceuti 
cally acceptable salt thereof . In some embodiments , the 
compound is a compound of Formula III , or a pharmaceu 
tically acceptable salt thereof . In some embodiments , the 
compound is selected from the group of compounds pro 
vided in Table 1A , Table 1B , Table 1C , Table 2A , Table 3A , 
Table 4 , Table 5 , and Table 6 , or a pharmaceutically accept 
able salt thereof . 
[ 0340 ] In some embodiments , the compound is selected 
from the group consisting of : 
[ 0341 ] 2- ( 3,4 - dimethoxyphenyl ) -N - methyl - N- ( 4 - ni 
trobenzyl ) ethan - 1 - amine ; 
[ 0342 ] N - methyl - N- ( 4 - nitrobenzyl ) cyclohexanamine ; 
[ 0343 ] 3- ( adamantan - 1 - yl ( methyl ) amino ) propanenitrile ; 
[ 0344 ] 1- ( adamantan - 2 - yl ) -4- ( methyl sulfonyl ) piperazine ; 
[ 0345 ] 4 - ( ( 4- ( 2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ; 
[ 0346 ] ( 4 - benzylpiperazin - 1 - yl ) ( 2,3 - dihydrobenzo [ b ] 1,4 ] 
dioxin - 2 - yl ) methanone ; 
[ 0347 ] 1 - cinnamyl - 4- ( 4 - methoxybenzyl ) piperazine ; 
[ 0348 ] 1- ( 4 - fluorobenzyl ) -4- ( 0 - tolyl ) piperazine ; and 
[ 0349 ] 1 - benzyl - 4- ( bicyclo [ 2.2.1 ] heptan - 2 - yl ) piperazine ; 
or a pharmaceutically acceptable salt thereof . 
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[ 0350 ] In some embodiments , the compound is selected 
from the group consisting of : [ 0351 ] 2- ( 3,4 - dimethoxyphenyl ) -N - methyl - N- (4 - ni 
trobenzyl ) ethan - 1 - amine ; [ 0352 ] N - methyl - N- ( 4 - nitrobenzylcyclohexanamine ; 
[ 0353 ] 3- ( adamantan - 1 - yl ( methyl ) amino ) propanenitrile hydrochloride ; 
[ 0354 ] 1- ( adamantan - 2 - yl ) -4- ( methyl sulfonyl ) piperazine ; [ 0355 ] 4- ( 4- ( 2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ; 
[ 0356 ] ( 4 - benzylpiperazin - 1 - yl ) ( 2,3 - dihydrobenzo [ b ] 1,4 ] 
dioxin - 2 - yl ) methanone hydrochloride ; [ 0357 ] 1 - cinnamyl - 4- ( 4 - methoxybenzyl ) piperazine ; [ 0358 ] 1- ( 4 - fluorobenzyl ) -4- ( o - tolyl ) piperazine ; and [ 0359 ] 1 - benzyl - 4- ( bicyclo [ 2.2.1 ] heptan - 2 - yl ) piperazine . [ 0360 ] In some embodiments , the compound is selected from the group consisting of : 
[ 0361 ] ( 2- ( 3,4 - dimethoxyphenyl ) -N - methyl - N- ( 4 - ni 
trobenzyl ) ethan - 1 - amine ) ; 
[ 0362 ] ( 4 - ( ( 4- ( 2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ) ; and 
[ 0363 ] ( 3- ( adamantan - 1 - yl ( methyl ) amino ) propanenitrile ; 
or a pharmaceutically acceptable salt thereof . 
[ 0364 ] In some embodiments , the compound is selected from the group consisting of : [ 0365 ] ( 2- ( 3,4 - dimethoxyphenyl ) -N - methyl - N- ( 4 - ni 
trobenzyl ) ethan - 1 - amine ) ; [ 0366 ] ( 4- ( 4- ( 2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ) ; and [ 0367 ] ( 3- ( adamantan - 1 - yl ( methyl ) amino ) propanenitrile 
hydrochloride ) . 
[ 0368 ] In some embodiments , the compound is selected from the group consisting of : 
[ 0369 ] ( 2- ( 3,4 - dimethoxyphenyl ) -N - methyl - N- ( 4 - ni 
trobenzyl ) ethan - 1 - amine ) ; [ 0370 ] ( 4- ( 4- ( 2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ) ; and 
[ 0371 ] ( 3- ( adamantan - 1 - yl ( methyl ) amino ) propanenitrile ; 
or a pharmaceutically acceptable salt thereof . 
[ 0372 ] In some embodiments , the compound is selected from the group consisting of : 
[ 0373 ] ( 2- ( 3,4 - dimethoxyphenyl ) -N - methyl - N- ( 4 - ni 
trobenzyl ) ethan - 1 - amine ) ; [ 0374 ] ( 4 - ( [ 4- ( 2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ) ; and 
[ 0375 ] ( 3- ( adamantan - 1 - yl ( methyl ) amino propanenitrile 
hydrochloride ) . 
[ 0376 ] In some embodiments , the cell is a eukaryotic cell 
or a cyanobacteria . In some embodiments , the cell is a 
eukaryotic cell . In some embodiments , the cell is a cyano 
bacteria . In some embodiments , the cell is selected from the group consisting of an algal cell , a drosophila cell , a yeast 
cell , or a fungus cell ( e.g. , an algal cell , a drosophila cell , 
yeast cell , or a fungus cell provided herein ) . 
[ 0377 ] In some embodiments , the cell is an algal cell . In 
some embodiments , the cell is selected from the group 
consisting of : 
[ 0378 ] Chlamydomonas reinhardtii ; 
[ 0379 ] Chlorella sorokiniana ; [ 0380 ] Tetrachlorella alterans ; [ 0381 ] C protothecoides ; 
[ 0382 ] C. vulgaris , and 
[ 0383 ] Nannochloropsis sp . 
[ 0384 ] In some embodiments , the cell is an algal cell . In 
some embodiments , the cell is selected from the group 
consisting of : 
[ 0385 ] Chlamydomonas reinhardtii CC 125 ; 
[ 0386 ] Chlorella sorokiniana UTEX 1230 ; 
[ 0387 ) Tetrachlorella alterans UTEX 2453 ; [ 0388 ] C. protothecoides , 
[ 0389 ] C. vulgaris UTEX 395 ; and 
[ 0390 ] Nannochloropsis sp . 
[ 0391 ] In some embodiments , the increasing lipid produc 
tion comprises increasing fatty acid production . In some 
embodiments , the increasing fatty acid production com 
prises increasing C10-30 fatty acid production . In some 
embodiments , the increasing fatty acid production com 
prises increasing C10-20 fatty acid production . In some 
embodiments , the increasing fatty acid production com 
prises increasing C16-18 fatty acid production . In some 
embodiments , increasing lipid production comprises 
increasing polyunsaturated fatty acid production . In some 
embodiments , the increasing polyunsaturated fatty acid pro 
duction comprises increasing C10-30 polyunsaturated fatty 
acid production . In some embodiments , the increasing poly 
unsaturated fatty acid production comprises increasing Clo 
20 polyunsaturated fatty acid production . In some embodi 
ments , the increasing polyunsaturated fatty acid production 
comprises increasing C16-18 polyunsaturated fatty acid pro 
duction . 
[ 0392 ] In some embodiments , the increasing lipid produc 
tion comprises increasing triacylglycerol production . In 
some embodiments , the increasing triacylglycerol produc 
tion comprises increasing C30-60 triacylglycerol production . 
In some embodiments , the increasing triacylglycerol pro duction comprises increasing C40-60 triacylglycerol produc 
tion . In some embodiments , the triacylglycerol comprises 
fatty acids of C10-20 in chain length . In some embodiments , 
the triacylglycerol comprises fatty acids of C15-20 in chain 
length . In some embodiments , the triacylglycerol comprises 
fatty acids of 16 carbons in chain length . In some embodi 
ments , the triacylglycerol comprises fatty acids of 18 car 
bons in chain length . In some embodiments , the triacylglyc 
erol comprises fatty acids of 16 carbons and 18 carbons in 
chain length . 
[ 0393 ] In some embodiments , the increasing lipid produc 
tion comprises increasing fatty acid production and increas 
ing triacylglycerol production . In some embodiments , the increasing lipid production comprises increasing polyun 
saturated fatty acid production and increasing triacylglyc 
erol production . 
[ 0394 ] In some embodiments , the method further com 
prises increasing carbohydrate accumulation in the cell . For 
example , the carbohydrate accumulation may be increased 
by about 1.1 to about 5 fold , from about 1.25 to about 5 fold , 
from about 1.5 to about 5 fold , from about 1.75 to about 5 
fold , from about 2 to about 5 fold , from about 2.25 to about 
5 fold , from about 2.5 to about 5 fold , from about 2.75 to 
about 5 fold , from about 3 to about 5 fold , from about 3.25 
to about 5 fold , from about 3.5 to about 5 fold , from about 
3.75 to about 5 fold , from about 4 to about 5 fold , from about 
4.25 to about 5 fold , from about 4.5 to about 5 fold , or from 
about 4.75 to about 5 fold . In some embodiments , the 
method further comprises increasing carbohydrate accumu 
lation in the cell by about 1.25 to about 3.25 fold . In some 
embodiments , the method further comprises increasing car 
bohydrate accumulation in the cell by about 1.25 fold . In 
a 
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some embodiments , the method further comprises increas ing carbohydrate accumulation in the cell by about 2 fold . In 
some embodiments , the method further comprises increas 
ing carbohydrate accumulation in the cell by about 3.2 fold . 
[ 0395 ] In some embodiments , the method further com 
prises increasing carbohydrate production in the cell . For 
example , the carbohydrate production may be increased by 
about 1.1 to about 5 fold , from about 1.25 to about 5 fold , 
from about 1.5 to about 5 fold , from about 1.75 to about 5 
fold , from about 2 to about 5 fold , from about 2.25 to about 
5 fold , from about 2.5 to about 5 fold , from about 2.75 to 
about 5 fold , from about 3 to about 5 fold , from about 3.25 
to about 5 fold , from about 3.5 to about 5 fold , from about 
3.75 to about 5 fold , from about 4 to about 5 fold , from about 
4.25 to about 5 fold , from about 4.5 to about 5 fold , or from 
about 4.75 to about 5 fold . In some embodiments , the 
method further comprises increasing carbohydrate produc 
tion in the cell by about 1.25 to about 3.25 fold . In some 
embodiments , the method further comprises increasing car 
bohydrate production in the cell by about 1.25 fold . In some 
embodiments , the method further comprises increasing car bohydrate production in the cell by about 2 fold . In some 
embodiments , the method further comprises increasing car bohydrate production in the cell by about 3.2 fold . 
[ 0396 ] In some embodiments , the method further com 
prises increasing carbohydrate accumulation in the cell and increasing carbohydrate production in the cell . 
[ 0397 ] In some embodiments , the lipid production is increased by greater than about 1.5 fold as compared to a cell 
that has not been contacted by the compound , for example , 
greater than about 1.5 fold , greater than about 2 fold , greater 
than about 2.5 fold , greater than about 3 fold , greater than 
about 3.5 fold , greater than about 4 fold , greater than about 
4.5 fold , or greater than about 5 fold as compared to a cell 
that has not been contacted by the compound . In some 
embodiments , the lipid production is increased by greater 
than about 2 - fold as compared to a cell that has not been 
contacted by the compound . In some embodiments , the lipid 
production is increased by greater than about 2.5 - fold as 
compared to a cell that has not been contacted by the 
compound . 
[ 0398 ] In some embodiments , the contacting the cell with 
the compound does not reduce the rate of cellular growth 
compared to a cell that has not been contacted by the 
compound . 
[ 0399 ] In some embodiments , contacting the cell with the 
compound does not reduce the rate of photosynthesis of the 
cell compared to a cell that has not been contacted by the 
compound . For example , the rate of photosynthesis of the 
cell is not reduced if the amount of Chlorophyll A and B , 
carotenoid , and RuBisCO ( Ribulose - 1,5 - bisphosphate car boxylase / oxygenase ) in a cell contacted by a compound 
provided herein are about equivalent to a cell that has not 
been contacted by the compound . In some embodiments , the 
amount of Chlorophyll A and B , carotenoid , and RuBisCO ( Ribulose - 1,5 - bisphosphate carboxylase / oxygenase ) in a 
cell that has been contacted by a compound provided herein 
are about equivalent to a cell that has not been contacted by 
the compound 
[ 0400 ] In some embodiments , the contacting does not 
adversely affect the viability of the cell . For example , the 
viability of the cell may include , but is not limited to , 
cellular growth , total cellular protein levels , the level of 
Chlorophyll A in a cell , the level of Chlorophyll B in a cell , 
the level of carotenoid in a cell , the level of RuBisCO ( Ribulose - 1,5 - bisphosphate carboxylase / oxygenase ) in a 
cell , the level of carbohydrates in a cell , the level of nitrogen 
in a cell , the level of sulfur in a cell , and the level of metal 
content in a cell , or any combination thereof . [ 0401 ] In some embodiments , the lipid production is 
increased without exposing the cell to environmental stress . 
In some embodiments , the environmental stress comprises 
nutrient deprivation . In some embodiments , the environ 
mental stress comprises depriving the cell of nitrogen , 
depriving the cell of sulfur , depriving the cell of metal , or 
any combination thereof . [ 0402 ] The present application further provides a method 
of producing biofuel , the method comprising : [ 0403 ] a ) contacting a cell with an effective amount of a 
compound provided herein ( e.g. , a compound of any one of 
Formulae I , la , Ib , Ic , II , IIa , III , and IIIa , or a pharmaceu 
tically acceptable salt thereof ) ; 
[ 0404 ] b ) waiting a time sufficient to allow for increased 
lipid accumulation ; and [ 0405 ] c ) processing the cells into biofuel . [ 0406 ] In some embodiments , the compound is a com 
pound of Formula Ia , or a pharmaceutically acceptable salt 
thereof , or a compound of Formula Ib , or a pharmaceutically 
acceptable salt thereof , or a compound of Formula Ic , or a pharmaceutically acceptable salt thereof , or a compound of 
Formula Ila , or a pharmaceutically acceptable salt thereof , 
or a compound of Formula IIIa , or a pharmaceutically 
acceptable salt thereof . In some embodiments , the com 
pound is a compound of Formula I , or a pharmaceutically 
acceptable salt thereof . In some embodiments , the com 
pound is a compound of Formula II , or a pharmaceutically 
acceptable salt thereof . In some embodiments , the com pound is a compound of Formula III , or a pharmaceutically 
acceptable salt thereof . In some embodiments , the com 
pound is selected from the group of compounds provided in 
Table 1A , Table 1B , Table 1C , Table 2A , Table 3A , Table 4 , 
Table 5 , and Table 6 , or a pharmaceutically acceptable salt 
thereof . 
[ 0407 ] In some embodiments , the compound is selected 
from the group consisting of : [ 0408 ] 2- ( 3,4 - dimethoxyphenyl ) -N - methyl - N- ( 4 - ni 
trobenzyl ) ethan - 1 - amine ; [ 0409 ] N - methyl - N- ( 4 - nitrobenzyl ) cyclohexanamine ; 
[ 0410 ] 3 - adamantan - 1 - yl ( methyl ) amino ) propanenitrile ; [ 0411 ] 1 - adamantan - 2 - yl ) -4- ( methyl sulfonyl ) piperazine ; 
[ 0412 ] 4 - ( [ 4- ( 2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ; 
[ 0413 ] ( 4 - benzylpiperazin - 1 - yl ) ( 2,3 - dihydrobenzo [ b ] 1,4 ] 
dioxin - 2 - yl ) methanone ; [ 0414 ] 1 - cinnamyl - 4- ( 4 - methoxybenzyl ) piperazine ; 
[ 0415 ] 1- ( 4 - fluorobenzyl ) -4- ( o - tolyl ) piperazine ; and [ 0416 ] 1 - benzyl - 4- ( bicyclo [ 2.2.1 ] heptan - 2 - yl ) piperazine ; 
or a pharmaceutically acceptable salt thereof . 
[ 0417 ] In some embodiments , the compound is selected 
from the group consisting of : [ 0418 ] 2- ( 3,4 - dimethoxyphenyl ) -N - methyl - N- ( 4 - ni 
trobenzyl ) ethan - 1 - amine ; [ 0419 ] N - methyl - N- ( 4 - nitrobenzyl ) cyclohexanamine ; 
[ 0420 ] 3- ( adamantan - 1 - yl ( methyl ) amino ) propanenitrile hydrochloride ; 
[ 0421 ] 1 - adamantan - 2 - yl ) -4- ( methyl sulfonyl ) piperazine ; [ 0422 ] 4 - ( ( 4- ( 2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ; 
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[ 0423 ] ( 4 - benzylpiperazin - 1 - yl ) ( 2,3 - dihydrobenzo [ b ] 1,4 ] 
dioxin - 2 - yl ) methanone hydrochloride ; [ 0424 ] 1 - cinnamyl - 4- ( 4 - methoxybenzyl ) piperazine ; [ 0425 ] 1- ( 4 - fluorobenzyl ) -4- ( o - tolyl ) piperazine ; and [ 0426 ] 1 - benzyl - 4- ( bicyclo [ 2.2.1 ] heptan - 2 - yl ) piperazine . [ 0427 ] In some embodiments , the compound is selected from the group consisting of : [ 0428 ] ( 2- ( 3,4 - dimethoxyphenyl ) -N - methyl - N- ( 4 - ni 
trobenzyl ) ethan - 1 - amine ) ; [ 0429 ] ( 4- ( 4- ( 2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ) ; and [ 0430 ] ( 3- ( adamantan - 1 - yl ( methyl ) amino ) propanenitrile ; 
or a pharmaceutically acceptable salt thereof . [ 0431 ] In some embodiments , the compound is selected 
from the group consisting of : [ 0432 ] ( 2- ( 3,4 - dimethoxyphenyl ) -N - methyl - N- ( 4 - ni 
trobenzyl ) ethan - 1 - amine ) ; [ 0433 ] ( 4 - ( [ 4- ( 2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ) ; and 
[ 0434 ] ( 3- ( adamantan - 1 - yl ( methyl ) amino ) propanenitrile hydrochloride ) . 
[ 0435 ] In some embodiments , the compound is selected from the group consisting of : [ 0436 ] ( 2-3,4 - dimethoxyphenyl ) -N - methyl - N- ( 4 - ni 
trobenzyl ) ethan - 1 - amine ) ; [ 0437 ] ( 4 - ( [ 4- ( 2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ) ; and 
[ 0438 ] ( 3- ( adamantan - 1 - yl ( methyl ) amino ) propanenitrile ; 
or a pharmaceutically acceptable salt thereof . 
[ 0439 ] In some embodiments , the compound is selected 
from the group consisting of : [ 0440 ] ( 2- ( 3,4 - dimethoxyphenyl ) -N - methyl - N- ( 4 - ni 
trobenzyl ) ethan - 1 - amine ) ; [ 0441 ] ( 4 - ( ( 4- ( 2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ) ; and 
[ 0442 ] ( 3- ( adamantan - 1 - yl ( methyl ) amino ) propanenitrile ; 
or a pharmaceutically acceptable salt thereof . [ 0443 ] In some embodiments , the compound is selected from the group consisting of : [ 0444 ] ( 2- ( 3,4 - dimethoxyphenyl ) -N - methyl - N- ( 4 - ni 
trobenzyl ) ethan - 1 - amine ) ; 
[ 0445 ] ( 4 - ( [ 4- ( 2 - methoxyphenyl ) piperazin - 1 - yl ) methyl ) 
phenol ) ; and 
[ 0446 ] ( 3- ( adamantan - 1 - yl ( methyl ) amino propanenitrile 
hydrochloride ) . 
[ 0447 ] In some embodiments , the cell is a eukaryotic cell 
or a cyanobacteria . In some embodiments , the cell is a 
eukaryotic cell . In some embodiments , the cell is a cyano 
bacteria . In some embodiments , the cell is selected from the 
group consisting of an algal cell , a drosophila cell , a yeast 
cell , or a fungus cell ( e.g. , an algal cell , a drosophila cell , a 
yeast cell , or a fungus cell provided herein ) . 
[ 0448 ] In some embodiments , the cell is an algal cell . In 
some embodiments , the cell is selected from the group 
consisting of : 
[ 0449 ] Chlamydomonas reinhardtii ; 
[ 0450 ] Chlorella sorokiniana ; 
[ 0451 ] Tetrachlorella alterans ; [ 0452 ] C. protothecoides , 
[ 0453 ) C. vulgaris ; and [ 0454 ] Nannochloropsis sp . 
[ 0455 ] In some embodiments , the cell is an algal cell . In 
some embodiments , the cell is selected from the group 
consisting of : 
[ 0456 ] Chlamydomonas reinhardtii CC125 ; [ 0457 ] Chlorella sorokiniana UTEX 1230 ; 
[ 0458 ] Tetrachlorella alterans UTEX 2453 ; [ 0459 ] C. protothecoides ; 
[ 0460 ] C. vulgaris UTEX 395 ; and [ 0461 ] Nannochloropsis sp . 
[ 0462 ] In some embodiments , the time sufficient to allow 
for increased lipid accumulation is from about 1 hour to 
about 5 days , for example , from about 1 hour to about 5 
days , from about 1 hour to about 4 days , from about 1 hour 
to about 3 days , from about 1 hour to about 2 days , from 
about 1 hour to about 1 day , from about 1 hour to about 18 
hours , from about 1 hour to about 12 hours , from about 1 
hour to about 6 hours , from about 1 hour to about 2 hours , 
from about 2 hours to about 4 days , from about 2 hours to 
about 3 days , from about 2 hours to about 2 days , from about 
2 hours to about 1 day , from about 2 hours to about 18 hours , 
from about 2 hours to about 12 hours , from about 2 hours to 
about 6 hours , from about 6 hours to about 4 days , from 
about 6 hours to about 3 days , from about 6 hours to about 
2 days , from about 6 hours to about 1 day , from about 6 
hours to about 18 hours , from about 6 hours to about 12 
hours , from about 12 hours to about 4 days , from about 12 
hours to about 3 days , from about 12 hours to about 2 days , 
from about 12 hours to about 1 day , from about 12 hours to 
about 18 hours , from about 18 hours to about 4 days , from 
about 18 hours to about 3 days , from about 18 hours to about 
2 days , from about 18 hours to about 1 day , from about 1 day 
to about 4 days , from about 1 day to about 3 days , from 
about 1 day to about 2 days , from about 2 days to about 4 
days , from about 2 days to about 3 days , or from about 3 
days to about 4 days . In some embodiments , the time 
sufficient to allow for increased lipid accumulation is about 
1 day . In some embodiments , the time sufficient to allow for 
increased lipid accumulation is about 2 days . In some 
embodiments , the time sufficient to allow for increased lipid 
accumulation is about 3 days . 
[ 0463 ] Methods of processing cells into biofuel are known 
in the art and would be readily understood by one of 
ordinary skill . For example , the cells may be processed into 
biofuels selected from the group consisting of biodiesel , 
bioalcohol ( e.g. , bioethanol , biopropanol , biobutanol ) , and 
cellulosic ethanol . Examples of methods for processing cells 
into biofuel may be found , e.g. , in Pandey et al . , Biofuels 
from Algae , 1st Ed . , Elsevier B.V. ( 2014 ) , the disclosure of 
which is incorporated herein in its entirety . [ 0464 ] The present application further provides a nutra 
ceutical comprising one or more lipids produced according 
to a method provided herein . In some embodiments , the one 
or more lipids is produced in a cell provided herein , wherein 
the cell has been contacted with a compound provided 
herein ( e.g. , a compound of any one of Formulae I , Ia , Ib , Ic , 
II , IIa , III , and IIIa , or a pharmaceutically acceptable salt 
thereof ) . In some embodiments , the lipid is docosahexaenoic 
acid ( DHA ) . In some embodiments , the nutraceutical is 
formulated for oral administration , for example , as a pill , a 
tablet , a syrup , a drink , and the like . 
Definitions 
[ 0465 ] For the terms " for example ” and “ such as ” and 
grammatical equivalences thereof , the phrase " and without 
limitation ” is understood to follow unless explicitly stated 
otherwise . As used herein , the term “ about is meant to 
account for variations due to experimental error . All mea 
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n - m 
surements reported herein are understood to be modified by 
the term “ about ” , whether or not the term is explicitly used , 
unless explicitly stated otherwise . As used herein , the sin 
gular forms “ a , ” “ an , ” and “ the ” include plural referents 
unless the context clearly dictates otherwise . [ 0466 ] As used herein , the phrase “ optionally substituted ” 
means unsubstituted or substituted . As used herein , the term 
“ substituted ” means that a hydrogen atom is removed and 
replaced by a substituent . It is to be understood that substi 
tution at a given atom is limited by valency . [ 0467 ] Throughout the definitions , the term “ Ch indi 
cates a range which includes the endpoints , wherein n and m 
are integers and indicate the number of carbons . Examples 
include C1-4 , C1-6 , and the like . [ 0468 ] As used herein , the term “ Cn - m alkyl ” , employed 
alone or in combination with other terms , refers to a satu 
rated hydrocarbon group that may be straight - chain or 
branched , having n to m carbons . Examples of alkyl moi 
eties include , but are not limited to , chemical groups such as 
methyl , ethyl , n - propyl , isopropyl , n - butyl , tert - butyl , isobu 
tyl , sec - butyl ; higher homologs such as 2 - methyl - 1 - butyl , 
n - pentyl , 3 - pentyl , n - hexyl , 1,2,2 - trimethylpropyl , and the 
like . In some embodiments , the alkyl group contains from 1 
to 6 carbon atoms , from 1 to 4 carbon atoms , from 1 to 3 
carbon atoms , or 1 to 2 carbon atoms . 
[ 0469 ] As used herein , “ Ch - m alkenyl ” refers to an alkyl 
group having one or more double carbon - carbon bonds and 
having n to m carbons . Example alkenyl groups include , but 
are not limited to , ethenyl , n - propenyl , isopropenyl , n - bute 
nyl , sec - butenyl , and the like . In some embodiments , the 
alkenyl moiety contains 2 to 6 , 2 to 4 , or 2 to 3 carbon atoms . 
[ 0470 ] As used herein , “ Cn - m alkynyl ” refers to an alkyl 
group having one or more triple carbon - carbon bonds and 
having n to m carbons . Example alkynyl groups include , but 
are not limited to , ethynyl , propyn - 1 - yl , propyn - 2 - yl , and the 
like . In some embodiments , the alkynyl moiety contains 2 to 
6 , 2 to 4 , or 2 to 3 carbon atoms . 
[ 0471 ] As used herein , the term alkylene ” , 
employed alone or in combination with other terms , refers to 
a divalent alkyl linking group having n to m carbons . 
Examples of alkylene groups include , but are not limited to , 
ethan - 1,2 - diyl , propan - 1,3 - diyl , propan - 1,2 - diyl , butan - 1,4 
diyl , butan - 1,3 - diyl , butan - 1,2 - diyl , 2 - methyl - propan - 1,3 
diyl , and the like . In some embodiments , the alkylene moiety 
contains 2 to 6 , 2 to 4 , 2 to 3 , 1 to 6 , 1 to 4 , or 1 to 2 carbon 
atoms . 
[ 0472 ] As used herein , the term “ Cn - m alkenylene ” , 
employed alone or in combination with other terms , refers to 
a divalent alkenyl linking group having n to m carbons . 
Examples of alkenylene groups include , but are not limited 
CH = CH- , CH = CHCH , 
CH2CH2CH = CHCH2 , and the like . In some embodi 
ments , the alkylene moiety contains 2 to 6 , 2 to 4 , or 2 to 3 
carbon atoms . 
[ 0473 ] As used herein , the term " Cn - m alkoxy " , employed 
alone or in combination with other terms , refers to a group 
of formulae “ -O - alkyl ” , or “ _O - alkylene ) , - " , or " -alky 
lene - Op wherein the alkyl or alkylene group has n to m 
carbons and p is an integer from 1 to 6. Example alkoxy 
groups include methoxy , ethoxy , propoxy ( e.g. , n - propoxy 
and isopropoxy ) , tert - butoxy , ( CHOCHLOCH ) 
- ( CH2CH2OCH2CH2O ) — , ( OCH_ ) ( OCH OCH , CH ) , ( CH.CH OCH CH 0 ) 
- ( CH_CH_OCH , CH_OCH CH2 ) - and the like . In some 
embodiments , the alkyl group has 1 to 6 , 1 to 4 , or 1 to 3 
carbon atoms . In some embodiments , p is 1. In some 
embodiments , p is 2. In some embodiments , p is 3. In some 
embodiments , p is 4. In some embodiments , p is 5. In some 
embodiments , p is 6 . [ 0474 ] As used herein , the term “ Cn - m alkylamino ” refers 
to a group of formula NH ( alkyl ) , wherein the alkyl group 
has n to m carbon atoms . In some embodiments , the alkyl 
group has 1 to 6 , 1 to 4 , or 1 to 3 carbon atoms . 
[ 0475 ] As used herein , the term “ Cn - m alkoxycarbonyl ” 
refers to a group of formula C ( O ) O - alkyl , wherein the 
alkyl group has n to m carbon atoms . In some embodiments , 
the alkyl group has 1 to 6 , 1 to 4 , or 1 to 3 carbon atoms . 
[ 0476 ] As used herein , the term “ Cn - m alkylcarbonyl ” 
refers to a group of formula C ( O ) -alkyl , wherein the alkyl 
group has n to m carbon atoms . In some embodiments , the 
alkyl group has 1 to 6 , 1 to 4 , or 1 to 3 carbon atoms . 
[ 0477 ] As used herein , the term “ Cn - m alkylcarbo 
nylamino ” refers to a group of formula - NHC ( O ) -alkyl , 
wherein the alkyl group has n to m carbon atoms . In some 
embodiments , the alkyl group has 1 to 6 , 1 to 4 , or 1 to 3 
carbon atoms . 
[ 0478 ] As used herein , the term “ Cn - m alkylsulfo 
nylamino ” refers to a group of formula NHS ( O ) 2 - alkyl , 
wherein the alkyl group has n to m carbon atoms . In some 
embodiments , the alkyl group has 1 to 6 , 1 to 4 , or 1 to 3 
carbon atoms . 
[ 0479 ] As used herein , the term “ aminosulfonyl ” refers to 
a group of formula S ( O ) 2NH2 [ 0480 ] As used herein , the term “ Cn - m alkylaminosulfo 
nyl ” refers to a group of formula -S ( O ) 2NH ( alkyl ) , 
wherein the alkyl group has n to m carbon atoms . In some 
embodiments , the alkyl group has 1 to 6 , 1 to 4 , or 1 to 3 
carbon atoms . 
[ 0481 ] As used herein , the term “ di ( Cn - m alkyl ) aminosul 
fonyl ” refers to a group of formula S ( O ) 2N ( alkyl ) 2 , 
wherein each alkyl group independently has n to m carbon 
atoms . In some embodiments , each alkyl group has , inde 
pendently , 1 to 6 , 1 to 4 , or 1 to 3 carbon atoms . [ 0482 ] As used herein , the term “ aminosulfonylamino " 
refers to a group of formula – NHS ( O ) 2NH2 . [ 0483 ] As used herein , the term “ Cn - m alkylaminosulfo 
nylamino ” refers to a group of formula – NHS ( O ) 2NH ( alkyl ) , wherein the alkyl group has n to m carbon atoms . In 
some embodiments , the alkyl group has 1 to 6 , 1 to 4 , or 1 
to 3 carbon atoms . 
[ 0484 ] As used herein , the term “ di ( Cn - m alkyl ) aminosul 
fonylamino ” refers to a group of formula NHS ( O ) 2N ( alkyl ) 2 , wherein each alkyl group independently has n to m 
carbon atoms . In some embodiments , each alkyl group has , 
independently , 1 to 6 , 1 to 4 , or 1 to 3 carbon atoms . [ 0485 ] As used herein , the term “ aminocarbonylamino ” , 
employed alone or in combination with other terms , refers to 
a group of formula —NHC ( O ) NH2 . [ 0486 ] As used herein , the term “ Cn - m alkylaminocarbo 
nylamino ” refers to a group of formula NHC ( O ) NH ( alkyl ) , wherein the alkyl group has n to m carbon atoms . In 
some embodiments , the alkyl group has 1 to 6 , 1 to 4 , or 1 
to 3 carbon atoms . 
[ 0487 ] As used herein , the term “ di ( Cn - m alkyl ) aminocar bonylamino ” refers to a group of formula NHC ( O ) N ( alkyl ) 2 , wherein each alkyl group independently has n to m 
carbon atoms . In some embodiments , each alkyl group has , 
independently , 1 to 6 , 1 to 4 , or 1 to 3 carbon atoms . 
“ Cn - m 
to , 
2 
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[ 0488 ] As used herein , the term “ Cn - m alkylcarbamyl ” 
refers to a group of formula C ( O ) -NH ( alkyl ) , wherein 
the alkyl group has n to m carbon atoms . In some embodi 
ments , the alkyl group has 1 to 6 , 1 to 4 , or 1 to 3 carbon 
atoms . 
[ 0489 ] As used herein , the term “ thio ” refers to a group of 
formula SH . 
[ 0490 ] As used herein , the term “ Cn - m alkylsulfinyl ” refers 
to a group of formula -S ( O ) -alkyl , wherein the alkyl group 
has n to m carbon atoms . In some embodiments , the alkyl 
group has 1 to 6 , 1 to 4 , or 1 to 3 carbon atoms . 
[ 0491 ] As used herein , the term “ Cn - m alkylsulfonyl ” 
refers to a group of formula -S ( O ) 2 - alkyl , wherein the alkyl 
group has n to m carbon atoms . In some embodiments , the 
alkyl group has 1 to 6 , 1 to 4 , or 1 to 3 carbon atoms . 
[ 0492 ] As used herein , the term “ amino ” refers to a group 
of formula -NH2 . [ 0493 ] As used herein , the term “ aryl , ” employed alone or 
in combination with other terms , refers to an aromatic 
hydrocarbon group , which may be monocyclic or polycyclic 
( e.g. , having 2 , 3 or 4 fused rings ) . The term “ Ch - m aryl ” 
refers to an aryl group having from n to m ring carbon atoms . 
Aryl groups include , e.g. , phenyl , naphthyl , anthracenyl , 
phenanthrenyl , indanyl , indenyl , and the like . In some 
embodiments , aryl groups have from 6 to about 20 carbon 
atoms , from 6 to about 15 carbon atoms , or from 6 to about 
10 carbon atoms . In some embodiments , the aryl group is a 
substituted or unsubstituted phenyl . 
[ 0494 ] As used herein , the term " carbamyl ” to a group of 
formula -C ( O ) NH2 . [ 0495 ] As used herein , the term " carbonyl ” , employed 
alone or in combination with other terms , refers to a 
C = O ) - group , which may also be written as C ( O ) . [ 0496 ] As used herein , the term " di ( Cn - m - alkyl ) amino " 
refers to a group of formulaN (alkyl ) 2 , wherein the two 
alkyl groups each has , independently , n to m carbon atoms . 
In some embodiments , each alkyl group independently has 
1 to 6 , 1 to 4 , or 1 to 3 carbon atoms . 
[ 0497 ] As used herein , the term “ di ( Cn - m - alkyl ) carbamyl ” 
refers to a group of formula - C ( O ) N ( alkyl ) 2 , wherein the two alkyl groups each has , independently , n to m carbon 
atoms . In some embodiments , each alkyl group indepen 
dently has 1 to 6 , 1 to 4 , or 1 to 3 carbon atoms . 
[ 0498 ] As used herein , " halo ” refers to F , C1 , Br , or I. In 
some embodiments , a halo is F , C1 , or Br . 
[ 0499 ] As used herein , the term “ Cn - m haloalkyl ” , 
employed alone or in combination with other terms , refers to 
an alkyl group having from one halogen atom to 2s + 1 
halogen atoms which may be the same or different , where 
“ g ” is the number of carbon atoms in the alkyl group , 
wherein the alkyl group has n to m carbon atoms . In some 
embodiments , the haloalkyl group is fluorinated only . In 
some embodiments , the alkyl group has 1 to 6 , 1 to 4 , or 1 
to 3 carbon atoms . 
[ 0500 ] As used herein , “ cycloalkyl ” refers to non - aromatic 
cyclic hydrocarbons including cyclized alkyl and / or alkenyl 
groups . Cycloalkyl groups can include mono- or polycyclic ( e.g. , having 2 , 3 or 4 fused rings ) groups and spirocycles . 
Cycloalkyl groups can have 3 , 4 , 5 , 6 , 7 , 8 , 9 , or 10 
ring - forming carbons ( C3-10 ) . Ring - forming carbon atoms of 
a cycloalkyl group can be optionally substituted by oxo or 
sulfido ( e.g. , C ( O ) or C ( S ) ) . Cycloalkyl groups also include 
cycloalkylidenes . Example cycloalkyl groups include cyclo 
propyl , cyclobutyl , cyclopentyl , cyclohexyl , cycloheptyl , 
cyclopentenyl , cyclohexenyl , cyclohexadienyl , cyclohep 
tatrienyl , norbornyl , norpinyl , norcarnyl , and the like . In 
some embodiments , cycloalkyl is cyclopropyl , cyclobutyl , 
cyclopentyl , cyclohexyl , cyclopentyl , or adamantyl . In some 
embodiments , the cycloalkyl has 5-10 ring - forming carbon 
atoms . In some embodiments , cycloalkyl is adamantyl . Also included in the definition of cycloalkyl are moieties that 
have one or more aromatic rings fused ( i.e. , having a bond in common with ) to the cycloalkyl ring , for example , benzo 
or thienyl derivatives of cyclopentane , cyclohexane , and the 
like . A cycloalkyl group containing a fused aromatic ring can 
be attached through any ring - forming atom including a 
ring - forming atom of the fused aromatic ring . 
[ 0501 ] As used herein , “ heteroaryl ” refers to a monocyclic 
or polycyclic aromatic heterocycle having at least one 
heteroatom ring member selected from sulfur , oxygen , and 
nitrogen . In some embodiments , the heteroaryl ring has 1 , 2 , 
3 , or 4 heteroatom ring members independently selected 
from nitrogen , sulfur and oxygen . In some embodiments , 
any ring - forming N in a heteroaryl moiety can be an 
N - oxide . In some embodiments , the heteroaryl has 5-13 ring 
atoms and 1 , 2 , 3 or 4 heteroatom ring members indepen 
dently selected from nitrogen , sulfur and oxygen . For 
example , a five - membered heteroaryl ring is a heteroaryl 
with a ring having five ring atoms wherein one or more ( e.g. , 
1 , 2 , or 3 ) ring atoms are independently selected from N , O , 
and S. Exemplary five - membered ring heteroaryls are thie 
nyl , furyl , pyrrolyl , imidazolyl , thiazolyl , oxazolyl , pyra 
zolyl , isothiazolyl , isoxazolyl , 1,2,3 - triazolyl , tetrazolyl , 1,2 , 
3 - thiadiazolyl , 1,2,3 - oxadiazolyl , 1,2,4 - triazolyl , 1,2,4 
thiadiazolyl , 1,2,4 - oxadiazolyl , 1,3,4 - triazolyl , 1,3,4 
thiadiazolyl , and 1,3,4 - oxadiazolyl . A six - membered heteroaryl ring , for example , is a heteroaryl with a ring 
having six ring atoms wherein one or more ( e.g. , 1 , 2 , or 3 ) 
ring atoms are independently selected from N , O , and S. 
Exemplary six - membered ring heteroaryls are pyridyl , pyrazinyl , pyrimidinyl , triazinyl and pyridazinyl . 
[ 0502 ] As used herein , “ heterocycloalkyl ” refers to non 
aromatic monocyclic or polycyclic heterocycles having one 
or more ring - forming heteroatoms selected from O , N , or S. 
Included in heterocycloalkyl are monocyclic 4-10 mem bered heterocycloalkyl groups . Heterocycloalkyl groups can 
also include spirocycles . Example heterocycloalkyl groups 
include pyrrolidin - 2 - one , 1,3 - isoxazolidin - 2 - one , pyranyl , 
tetrahydropuran , oxetanyl , azetidinyl , morpholino , thiomor 
pholino , piperazinyl , tetrahydrofuranyl , tetrahydrothienyl , 
piperidinyl , pyrrolidinyl , isoxazolidinyl , isothiazolidinyl , 
pyrazolidinyl , oxazolidinyl , thiazolidinyl , imidazolidinyl , 
azepanyl , benzazapene , and the like . Ring - forming carbon 
atoms and heteroatoms of a heterocycloalkyl group can be 
optionally substituted by oxo or sulfido ( e.g. , C ( O ) , S ( O ) , 
C ( S ) , or S ( O ) 2 , etc. ) . The heterocycloalkyl group can be 
attached through a ring - forming carbon atom or a ring 
forming heteroatom . In some embodiments , the heterocy 
cloalkyl group contains 0 to 3 double bonds . In some 
embodiments , the heterocycloalkyl group contains 0 to 2 
double bonds . Also included in the definition of heterocy 
cloalkyl are moieties that have one or more aromatic rings 
fused ( i.e. , having a bond in common with ) to the cycloalkyl 
ring , for example , benzo or thienyl derivatives of piperidine , 
morpholine , azepine , etc. A heterocycloalkyl group contain 
ing a fused aromatic ring can be attached through any 
ring - forming atom including a ring - forming atom of the 
fused aromatic ring . In some embodiments , the heterocy 
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cloalkyl has 4-10 , 4-7 or 4-6 ring atoms with 1 , 2 , or 3 ring 
heteroatoms independently selected from nitrogen , oxygen , 
or sulfur and having one or more oxidized ring members . [ 0503 ] At certain places , the definitions or embodiments 
refer to specific rings ( e.g. , an azetidine ring , a pyridine ring , 
etc. ) . Unless otherwise indicated , these rings can be attached 
to any ring member provided that the valency of the atom is 
not exceeded . For example , an azetidine ring may be 
attached at any position of the ring , whereas a pyridin - 3 - yl 
ring is attached at the 3 - position . [ 0504 ] The term “ compound ” as used herein is meant to 
include all stereoisomers , geometric isomers , tautomers , and isotopes of the structures depicted . Compounds herein iden 
tified by name or structure as one particular tautomeric form 
are intended to include other tautomeric forms unless oth 
erwise specified [ 0505 ] Compounds provided herein also include tauto 
meric forms . Tautomeric forms result from the swapping of 
a single bond with an adjacent double bond together with the 
concomitant migration of a proton . Tautomeric forms 
include prototropic tautomers which are isomeric protona 
tion states having the same empirical formula and total 
charge . Example prototropic tautomers include ketone 
enol pairs , amide imidic acid pairs , lactam lactim pairs , 
enamine — imine pairs , and annular forms where a proton 
can occupy two or more positions of a heterocyclic system , 
for example , 1H- and 3H - imidazole , 1H- , 2H- and 4H - 1,2 , 
4 - triazole , 1H- and 2H - isoindole , and 1H- and 2H - pyrazole . 
Tautomeric forms can be in equilibrium or sterically locked 
into one form by appropriate substitution . [ 0506 ] All compounds , and pharmaceutically acceptable 
salts thereof , can be found together with other substances 
such as water and solvents ( e.g. hydrates and solvates ) or can 
be isolated . 
[ 0507 ] In some embodiments , preparation of compounds 
can involve the addition of acids or bases to affect , for 
example , catalysis of a desired reaction or formation of salt 
forms such as acid addition salts . 
[ 0508 ] Example acids can be inorganic or organic acids 
and include , but are not limited to , strong and weak acids . 
Some example acids include hydrochloric acid , hydrobro 
mic acid , sulfuric acid , phosphoric acid , p - toluenesulfonic 
acid , 4 - nitrobenzoic acid , methanesulfonic acid , benzene 
sulfonic acid , trifluoroacetic acid , and nitric acid . Some 
weak acids include , but are not limited to acetic acid , 
propionic acid , butanoic acid , benzoic acid , tartaric acid , 
pentanoic acid , hexanoic acid , heptanoic acid , octanoic acid , 
nonanoic acid , and decanoic acid . 
[ 0509 ] Example bases include lithium hydroxide , sodium 
hydroxide , potassium hydroxide , lithium carbonate , sodium 
carbonate , potassium carbonate , and sodium bicarbonate . 
Some example strong bases include , but are not limited to , 
hydroxide , alkoxides , metal amides , metal hydrides , metal 
dialkylamides and arylamines , wherein ; alkoxides include 
lithium , sodium and potassium salts of methyl , ethyl and 
t - butyl oxides ; metal amides include sodium amide , potas 
sium amide and lithium amide ; metal hydrides include 
sodium hydride , potassium hydride and lithium hydride ; and 
metal dialkylamides include lithium , sodium , and potassium 
salts of methyl , ethyl , n - propyl , iso - propyl , n - butyl , tert 
butyl , trimethylsilyl and cyclohexyl substituted amides . 
[ 0510 ] In some embodiments , the compounds provided 
herein , or salts thereof , are substantially isolated . By “ sub 
stantially isolated ” is meant that the compound is at least 
partially or substantially separated from the environment in 
which it was formed or detected . Partial separation can 
include , for example , a composition enriched in the com 
pounds provided herein . Substantial separation can include 
compositions containing at least about 50 % , at least about 
60 % , at least about 70 % , at least about 80 % , at least about 
90 % , at least about 95 % , at least about 97 % , or at least about 
99 % by weight of the compounds provided herein , or salt 
thereof . Methods for isolating compounds and their salts are 
routine in the art . 
[ 0511 ] The phrase " pharmaceutically acceptable " is 
employed herein to refer to those compounds , materials , 
compositions , and / or dosage forms which are , within the 
scope of sound medical judgment , suitable for use in contact 
with the tissues of human beings and animals without 
excessive toxicity , irritation , allergic response , or other 
problem or complication , commensurate with a reasonable 
benefit / risk ratio . 
[ 0512 ] The present application also includes pharmaceu 
tically acceptable salts of the compounds described herein . 
As used herein , “ pharmaceutically acceptable salts ” refers to 
derivatives of the disclosed compounds wherein the parent 
compound is modified by converting an existing acid or base 
moiety to its salt form . Examples of pharmaceutically 
acceptable salts include , but are not limited to , mineral or 
organic acid salts of basic residues such as amines ; alkali or 
organic salts of acidic residues such as carboxylic acids ; and 
the like . The pharmaceutically acceptable salts of the present 
application include the conventional non - toxic salts of the 
parent compound formed , for example , from non - toxic inorganic or organic acids . The pharmaceutically acceptable 
salts of the present application can be synthesized from the 
parent compound which contains a basic or acidic moiety by 
conventional chemical methods . Generally , such salts can be 
prepared by reacting the free acid or base forms of these 
compounds with a stoichiometric amount of the appropriate 
base or acid in water or in an organic solvent , or in a mixture 
of the two ; generally , non - aqueous media like ether , ethyl 
acetate , alcohols ( e.g. , methanol , ethanol , iso - propanol , or 
butanol ) or acetonitrile ( MeCN ) are preferred . Lists of 
suitable salts are found in Remington's Pharmaceutical 
Sciences , 17th ed . , Mack Publishing Company , Easton , Pa . , 
1985 , p . 1418 and Journal of Pharmaceutical Science , 66 , 2 ( 1977 ) . Conventional methods for preparing salt forms are 
described , for example , Handbook of Pharmaceutical 
Salts : Properties , Selection , and Use , Wiley - VCH , 2002 . 
EXAMPLES 
[ 0513 ] The invention will be described in greater detail by 
way of specific examples . The following examples are 
offered for illustrative purposes , and are not intended to limit 
the invention in any manner . Those of skill in the art will 
readily recognize a variety of non - critical parameters which 
can be changed or modified to yield essentially the same 
results . 
Example 1 
High Throughput Screening Assay 
[ 0514 ] A large scale in vivo high throughput screen ( HTS ) 
was performed to identify small compounds that stimulate 
lipid production and accumulation using the model organism 
Chlamydomonas reinhardtii . The HTS employed a 384 - well 
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TABLE 7 - continued 
Dose Response Assay 
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1.25 
?M 
0.625 
UM 
0.25 
UM 
microplate format in which cells were allowed to grow in the 
presence of the test compounds at 10 uM final concentration 
for 72 hours . Accumulation of intracellular lipids was 
assessed using the lipophilic dye Nile Red to select high 
lipid producers and growth was monitored at OD600 to 
select compounds that did not eliminate cellular growth . [ 0515 ] The screening library included 43,736 compounds 
( ChemBridge , Corp ) . A total of 367 active compounds were 
identified that stimulated lipid accumulation to > 2.5 - fold 
and did not affect cell viability . A sub - set of compounds were 
retested using an 8 - point dose response assay ( 0.25-30 
Compounds were further assessed visually using a Nikon 
Ti - inverted microscope ( 60x ) to reconfirm lipid droplet 
accumulation was induced . The EC50 ( UM ) values and 
microscopy images of compounds 1 , 62 , and 136 are shown 
in FIG . 1. Treatment of the cells with compounds 1 , 62 , and 136 does not disrupt major organelles including nucleus , 
endoplasmic reticulum , and chloroplast ( FIG . 1 ) . 
[ 0516 ] Table 7 shows results of the 8 - point dose response 
assay . 
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5.68 
13.49 
17.22 
1.73 
17.01 
7.09 
7.79 
2.35 
2.51 
5.31 
1.15 
2 
1.38 
15.88 
7.43 
7.26 
12.59 
10.81 
1.56 
1.78 
1.19 
1.43 
0.94 
1.19 
10.05 
0.80 
1.99 
8.75 
1.57 
4.88 
0.97 
0.85 
9.67 
11.44 
1.39 
2.5 
0.89 
0.89 
3.4 
11.38 
3.64 
6.68 
0.79 
0.84 
0.99 
1.03 
1.86 
4.38 
2.19 
1.16 
1.68 
0.95 
0.81 
1.84 
1.23 
1.95 
1.39 
1.23 
0.99 
2.25 
15.48 
1.34 
3.96 
10.37 
1.96 
17.67 
9.14 
13.62 
11.32 
2.28 
5.88 
4.05 
16.13 
7.24 
2.7 
1.04 
1.31 
15.55 
4.02 
5.67 
8.64 
1.43 
1.19 
1.33 
4.06 
3.65 
19.07 
20.41 
1.37 
15.24 
8.09 
10.01 
3.78 
2.5 
8.49 
1.16 
2.61 
1.57 
17.74 
7.85 
6.28 
14.28 
13.88 
2.06 
2.63 
1.27 
3.08 
0.99 
1.69 
11.42 
0.91 
3.31 
9.26 
3.48 
5.29 
0.93 
1.36 
10.91 
4.45 
3.11 
10.51 
0.89 
1.13 
9.13 
13.55 
7.76 
7.88 
0.78 
0.97 
1.02 
3.9 
14.97 
9.91 
2.38 
0.84 
3.61 
2.51 
1.18 
3.5 
1.96 
1.89 
1.85 
2.23 
1.18 
3.94 
3.33 
6 
7.57 
1.82 
2.3 
1.61 
1.3 
48 6.94 
49 3.07 
50 13.02 
51 11.93 
52 11.4 
53 2.49 
54 1.58 
55 2.77 
56 1.92 
57 1.87 
58 1.56 
59 3.84 
60 1.65 
61 1.14 
62 21.07 
63 21.78 
64 7.98 
65 8.07 
66 5.72 
67 3.6 
68 2.03 
69 2.54 
70 11.07 
71 11.83 
72 9.85 
74 2.81 
75 6.95 
76 10.01 
77 4.05 
78 7.85 
79 16.86 
81 18.89 
82 13.39 
83 8.83 
84 1.34 
86 3.76 
88 4.8 
90 8.7 
91 8.29 
93 8.86 
94 6.35 
95 1.81 
96 11.77 
97 8.76 
98 11.04 
99 4.22 
100 18.12 
101 1.75 
103 9.86 
104 3.69 
106 9.7 
107 3.06 
109 9.73 
110 12.43 
111 9.13 
112 10.17 
113 3.03 
120 1.02 
121 12.49 
123 1.83 
124 1.38 
129 14.66 
130 7.38 
131 1.87 
132 4.57 
133 3.44 
134 2.14 
135 11.19 
136 19.83 
137 4.85 
138 12.1 
139 2.8 
10.55 
8.51 
8.62 
13.34 
10.15 
1.61 
1.78 
2.26 
1.74 
1.15 
1.42 
3.04 
1.35 
1.24 
19.19 
20.48 
3.48 
11.17 
4.89 
6.33 
2.74 
3.49 
11.05 
12.08 
10.08 
1.96 
2.89 
11.14 
10.93 
10.45 
15.62 
18.42 
17.76 
15.98 
2.19 
3.38 
15.2 
13.43 
16.37 
12.09 
11.58 
1.74 
17.34 
7.56 
10.69 
3.37 
9.57 
1.43 
10.84 
3.28 
12.36 
3.07 
12.09 
14.61 
12.3 
7.57 
4.24 
3.19 
11.68 
3.09 
1.57 
14.1 
15.13 
4.36 
5.24 
14.41 
1.97 
16.64 
18.82 
12.33 
16.27 
6.14 
1.07 
1.05 
0.87 
0.89 
1.22 
0.97 
0.90 
2.09 
1.06 
0.83 
0.87 
0.91 
4.74 
0.98 
0.92 
0.98 
1.04 
2.39 
0.95 
0.97 
5.93 
1.03 
0.87 
1.1 
1.39 
0.98 
4.43 
8.98 
7.3 
6.57 
9.09 
1.57 
1.73 
2.04 
2.71 
1.11 
1.15 
2.52 
1.4 
0.91 
8.95 
10.18 
7.63 
8.09 
5.36 
7.75 
1.95 
3.49 
7.57 
8.37 
9.28 
2.07 
2.35 
8.88 
2.78 
9.94 
8.1 
3.75 
8.09 
6.89 
1.64 
2.71 
8.16 
6.74 
6.76 
8.59 
9.97 
4.03 
10.03 
3.46 
8.92 
2.96 
3.77 
1.04 
5.85 
2.81 
5.08 
2.48 
5.27 
7.3 
6.41 
12.3 
5.96 
2.15 
5.87 
3.7 
0.88 
3.85 
6.34 
9.13 
2.62 
9.72 
1.31 
10.02 
8.7 
7.15 
9.72 
3.04 
0.84 
0.96 
0.92 
0.94 
0.97 
0.94 
7 
1.02 
3.47 
1.02 
1.19 
1.17 
1.39 
0.92 
0.99 
1.09 
1.01 
2.39 
1.15 
1.63 
2.53 
1.02 
1.13 
1.15 
1.08 
1.17 
3.06 
0.81 
1.15 
0.86 
0.93 
0.82 
0.93 
1.09 
0.93 
1.04 
1.06 
1.17 
1.06 
1.01 
2.01 
2.35 
1.05 
0.93 
1.23 
0.90 
8.42 
10.46 
10.74 
9.13 
7.75 
1.42 
2.79 
2.23 
2.58 
1.28 
1.22 
2.54 
1.22 
1.04 
10.44 
9.63 
10.61 
9.72 
9.73 
10.08 
2.1 
2.44 
8.64 
7.95 
2.81 
1.28 
2.25 
5.17 
2.28 
8.34 
9.69 
3.32 
10.46 
1.14 
2.05 
2.29 
10.2 
8.56 
10.52 
7.33 
16.62 
14.02 
10.24 
9.14 
3.28 
1.96 
3.04 
1.58 
1.17 
4.04 
6.74 
2.31 
5.91 
3.69 
8.78 
12.95 
11.79 
1.07 
9.06 
4.8 
1.18 
15.81 
4.88 
3.8 
2.87 
12.58 
1.77 
9.84 
12.81 
10.2 
9.85 
2.27 
1 
1.69 
2.42 
3.25 
3.34 
6.48 
1.1 
2.32 
2.27 
1.8 
0.90 
0.90 
2.18 
1.1 
0.95 
8.17 
3.92 
10.14 
5.42 
12.08 
13.05 
2.15 
3.01 
4.4 
2.29 
2.21 
0.91 
2.08 
10.31 
10.74 
10.24 
6.13 
1.97 
7.09 
1.01 
2.5 
2.39 
8.96 
6.5 
11.82 
3.6 
11.42 
10.7 
6.91 
3.15 
3.5 
1.4 
2.26 
0.88 
1.1 
5.27 
3.68 
2.05 
6.87 
3.61 
7.07 
3.53 
11.03 
1.12 
1.93 
10.38 
1.18 
12.76 
1.03 
1.66 
1.91 
7.4 
1.32 
2.47 
3.51 
2.77 
2.75 
2.68 
0.66 
0.93 
1.19 
3.9 
0.92 
1.38 
1.53 
1.77 
1.2 
1.06 
0.94 
1.91 
1.07 
0.96 
3.12 
1.61 
11.51 
2.04 
4.1 
2.29 
1.05 
0.96 
1.55 
1.15 
1.03 
0.85 
1.02 
8.99 
1.41 
1.41 
1.08 
0.85 
8.43 
0.79 
0.89 
1.01 
2.14 
8.53 
1.37 
0.96 
10.57 
1.5 
1.51 
3.14 
1.57 
0.84 
0.95 
1.08 
0.85 
3.68 
2.12 
1.01 
1.93 
1.76 
2.59 
0.86 
2.27 
0.64 
1.31 
4.34 
1.13 
1.34 
0.96 
1.02 
1.19 
2.02 
1.06 
0.88 
1.32 
1.91 
2.28 
1.09 
1 1 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
6.43 
3.57 
7.39 
7.81 
0.82 
3.34 
3.63 
4 
3.65 
2.65 
2.72 
1.76 
2.94 
0.88 
4.07 
8.37 
4.24 
5.78 
2.68 
2.02 
2.75 
1.37 
0.87 
1.13 
0.97 
1.22 
5.73 
1.43 
1.05 
0.92 
0.78 
0.89 
1.01 
1.49 
0.94 
0.97 
1.38 
1.13 
1.26 
0.99 
10.42 
9.13 
1.01 
0.99 
0.96 
0.81 
12.5 
12.11 
11.25 
8.14 
0.99 
4.4 
4.84 
1.58 
10.44 
1.91 
3.47 
1.93 
2.64 
1.18 
3.53 
15.71 
11.32 
8.39 
5.1 
3.61 
2.31 
0.95 
1.69 
4.98 
2.86 
2.82 
1.49 
10.23 
1.78 
3.17 
3.67 
2.25 
0.97 
1.12 
1.14 
0.94 
3.96 
2.46 
1.23 
2.89 
3.52 
8.14 
1.3 
10.63 
0.89 
3.47 
7.48 
0.99 
2.18 
0.94 
1.08 
1.16 
2.81 
0.93 
1.09 
1.82 
3.13 
3.51 
0.86 
1.03 
0.99 
1.23 
1.02 
0.98 
1.42 
0.89 
1.04 
0.86 
1.15 
0.91 
0.92 
1.86 
1.17 
0.95 
1.13 
0.99 
1.02 
1 
10.94 
9.14 
0.95 
1.57 
0.94 
0.91 
0.97 
0.86 
0.88 
1.09 
1.09 
1.18 
45 
46 
47 
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TABLE 7 - continued 
Dose Response Assay 
levels in Chlamydomonas reinhardtii cells , indicating stimu 
lation of starch storage in addition to lipid storage , as shown 
in FIG . 9. None of the test compounds significantly affected 
total protein levels , as shown in FIG . 10 . 30 0.25 15 
UM 
10 
UM 
5 
?M 
2.5 
UM 
1.25 
?M 
0.625 
UM 0.25 UM 
Example 5 
Lipid Accumulation in Algal Cells 
140 
141 
142 
143 
144 
145 
146 
147 
148 
149 
7.63 
4.1 
7.36 
14.27 
19.74 
11.88 
6.76 
2.84 
1.45 
8.77 
5.97 
3.53 
4 
17.97 
22.79 
13.65 
5.68 
3.72 
1.65 
16.41 
4.8 
4.5 
6.3 
9.99 
11.58 
7.27 
6.61 
5.17 
1.39 
3.82 
3.05 
13.19 
6.53 
9.45 
12.44 
8.15 
4.14 
9.42 
1.63 
5.3 
1.26 
11.63 
10.4 
9.14 
10.13 
7.77 
4.38 
11.21 
1.32 
3.45 
1.1 
9.16 
10.17 
2.68 
4.03 
9.73 
1.93 
9.71 
0.88 
1.18 
1.33 
3.57 
13.32 
1.39 
1.64 
2.56 
1.3 
11.86 
1.04 
0.84 
0.98 
1.39 
9.79 
0.85 
0.86 
0.81 
1.01 
2.58 
0.94 
0.84 
[ 0520 ] Compounds 1 , 62 , and 136 were assayed in algal 
species Chlamydomonas reinhardtii CC125 , Chlorella soro 
kiniana UTEX 1230 , Chlorella vulgaris UTEX 395 , and 
Tetrachlorella alterns UTEX 2453 at concentrations ranging 
from 0.63 uM to 50 uM . All three test compounds stimulated 
lipid accumulation in each of the algal species , as shown in 
FIG . 11A - 11C . Example 2 
Cellular Growth 
OTHER EMBODIMENTS [ 0517 ] Chlamydomonas reinhardtii cells were grown in 
the presence of DMSO ( control ) or 30 82 M of test com 
pound for 72 hours . At the indicated times 200 uL cells were 
removed from each well and optical density and nile red 
fluorescence were measured . Results of the algal cell growth 
study are shown in FIG . 2A - 2C . 
[ 0521 ] It is to be understood that while the invention has 
been described in conjunction with the detailed description 
thereof , the foregoing description is intended to illustrate 
and not limit the scope of the invention , which is defined by 
the scope of the appended claims . Other aspects , advantages , 
and modifications are within the scope of the following 
claims . Example 3 
1. A method of increasing lipid accumulation in a fresh 
water algal cell , comprising contacting the cell with an 
effective amount of a compound of Formula Ia : 
la 
R3 NO2 ( R9 )
Lipid Accumulation 
[ 0518 ] Representative compounds provided herein were 
shown to increase lipid accumulation using lipophilic dye 
Nile Red at concentrations ranging from 0.5 uM to 15.0uM 
in Chlamydomonas reinhardtii cells , as shown in FIG . 3 . 
Lipid accumulation over a period of 72 hours was also 
measured ( 30 uM test compound ) using lipophilic dye Nile 
Red , as shown in FIG . 4. The increase of specific fatty acids 
and triglyercide accumulation was also demonstrated using 
compounds 1 , 62 , and 136 as shown in FIGS . 5-6 ( com 
pounds tested 30 uM for fatty acid assay and 5 um for 
triglyceride assay ) . FIGS . 12A - 12C show representative 
images of C. reinhardtii cultures that were treated with 10 
uM of representative test compounds of Formula Ia , For 
mula IIa , and Formula IIIa . The corresponding lipid accu 
mulation was visualized using confocal microscopy after 72 
hours in culture . 
| Cy ! 
R4 
or a salt thereof , wherein : 
L is selected from the group consisting of , C1-4 alkylene , 
and ( C - 4 alkylene ) -NR -- ( C - 4 alkylene ) ; 
RL is selected from the group consisting of H and methyl ; 
R3 is H ; 
Example 4 R * is ; 
Cellular Chlorophyll , Protein , and Carbohydrate 
Levels 
[ 0519 ] Compounds 1 , 62 , and 136 ( 30 uM ) did not sig 
nificantly alter levels of chlorophyll A ( Chl A ) , chlorophyll 
B ( Chl B ) , or carotenoid levels in Chlamydomonas rein 
hardtii cells , as shown in FIG . 7. Further , compounds 1 and 
136 did not significantly affect the levels of proteins required 
for photosynthesis ( e.g. , Rubisco large sub unit , Rubisco 
small sub unit , PSa D Photosystem I , PSb A Photosystem II , 
phosphoribulokinase , and histone , and compound 62 exhib 
ited minor effects on the same proteins , as shown in FIG . 8 . 
All three test compounds ( 30 UM ) increased carbohydrate 
Cyl is selected from the group consisting of phenyl ; 
Rºy is selected from the group consisting of halo , C1-4 
alkyl , C1-4 alkoxy , phenyl , ( C1-4 alkylene ) - ( phenyl ) , 
C3-10 cycloalkyl , and ( C - 4 alkylene ) - ( C3-10 
cyloalkyl ) , wherein each phenyl and the phenyl group 
of- ( C1-4 alkylene ) - ( phenyl ) is optionally substituted 
by 1 or 2 substituents independently selected from the 
group consisting of OH , halo , C1-4 alkyl , and C1-4 
alkoxy ; 
n is 0 or 1 ; and 
p is 0 , 1 , 2 , or 3 ; or 
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a compound of Formula Ila : 
Ila 
R3 
R2 
RS 
N R4 
Rla 
or a salt thereof , wherein : 
L ' is selected from the group consisting of a bond and 
C - 4 alkylene : 
Rla is selected from the group consisting of , C5-10 
cycloalkyl , 8-10 membered heteroaryl , phenyl , and 
10-13 membered heteroaryl , wherein the C5-10 
cycloalkyl and phenyl are each optionally substituted 
by 1 , 2 , or 3 substituents independently selected from 
the group consisting of halo , OH , NO ,, C -4 alkyl , and 
C1-4 alkoxy , and wherein the 10-13 membered het 
eroaryl is optionally substituted by one halo group ; 
R2 is selected from the group consisting of H , halo , OH , 
NO2 , C1-4 alkyl , and C1-4 alkoxy ; 
R is selected from the group consisting of H , halo , and 
C1-4 alkoxy ; 
R is selected from the group consisting of H , OH , and 
C alkoxy ; 
RS is selected from the group consisting of H , halo , and 
C1-4 alkoxy ; and 
Ris ; or 
a compound of Formula IIIa : 
4. The method of claim 1 , wherein the compound is a 
compound of Formula IIIa . 
5. - 6 . ( canceled ) 
7. The method of claim 1 , wherein the freshwater algal 
cell is a Chlorophyceae cell . 
8. The method of claim 1 , wherein the freshwater algal 
cell is selected from the group consisting of a Chlamydomo 
nas cell , a Chlorella cell , a Tetrachlorella cell , and a Nannochloropsis cell . 
9. - 18 . ( canceled ) 
19. The method of claim 1 , wherein the contacting the cell 
with the compound does not reduce the rate of cellular 
growth compared to a cell that has not been contacted by the 
compound . 
20. - 21 . ( canceled ) 
22. The method of claim 1 , wherein the lipid accumula 
tion is increased without exposing the cell to environmental 
stress . 
23. The method of claim 22 , wherein the environmental 
stress comprises nutrient deprivation . 
24. - 49 . ( canceled ) 
50. The method of claim 2 , wherein L is C1-4 alkylene . 
51. The method of claim 2 , wherein each Rºy is an 
independently selected C1-4 alkoxy . 
52. The method of claim 2 , wherein p is 1 or 2 . 
53. The method of claim 3 , wherein L ' is a bond . 
54. The method of claim 3 , wherein Rla is phenyl sub 
stituted by C1-4 alkoxy . 
55. The method of claim 3 , wherein R2 is OH . 
56. The method of claim 3 , wherein R3 , R1 , and RS 
each H. 
57. The method of claim 4 , wherein L ' is NH . 
58. The method of claim 4 , wherein Rla is C1-4 cyano 
alkylene . 
59. The method of claim 4 , wherein R24 is H. 
60. The method of claim 1 , wherein the compound is 
selected from the group consisting of : 
are 
IIIa 
( 1 ) NO2 22 - Rza 
Rla 
( 62 ) 
OH 
or a salt thereof , wherein : 
L ' is selected from the group consisting of , NH and 
N ( C1-4 alkyl ) ; 
Ra is selected from the group consisting of H , C - 4 alkyl , 
C2-4 alkenyl , C1-4 cyanoalkylene , NH ( C1-4 alkyl ) , and 
NH ( C2-4 alkenyl ) ; 
L is ; and 
R2a is selected from the group consisting of H , C1-4 
hydroxyalkyl , SO2 ( C1-4 alkyl ) . 
2. The method of claim 1 , wherein the compound is a 
compound of Formula Ia . 
3. The method of claim 1 , wherein the compound is a 
compound of Formula IIa . 
pro 
US 2020/0071735 A1 Mar. 5. 2020 
58 
-continued 
( 136 ) 
: N 
or a salt thereof . 
